Close

Form 10-Q 4Front Ventures Corp. For: Jun 30

August 15, 2022 5:49 PM EDT
--12-31false0001783875Q2NONENONERepresents warrants that are exercisable as of June 30, 2022. 0001783875 2022-01-01 2022-06-30 0001783875 2022-04-01 2022-06-30 0001783875 2021-04-01 2021-06-30 0001783875 2021-01-01 2021-06-30 0001783875 2022-06-30 0001783875 2021-12-31 0001783875 2021-01-01 2021-12-31 0001783875 2022-04-30 0001783875 2022-09-01 0001783875 2021-01-01 2021-03-31 0001783875 2022-01-01 2022-03-31 0001783875 2020-01-01 2020-12-31 0001783875 2022-08-15 0001783875 2022-04-01 2022-04-30 0001783875 2021-11-01 2021-11-30 0001783875 2022-01-26 2022-01-26 0001783875 2022-01-28 2022-01-28 0001783875 2022-05-17 2022-05-17 0001783875 2020-12-31 0001783875 2021-06-30 0001783875 2022-03-31 0001783875 2021-03-31 0001783875 ffntf:OmOfMedicineMember 2022-06-30 0001783875 us-gaap:CommonClassAMember 2022-06-30 0001783875 ffntf:ClassASubordinateVotingSharesMember 2022-06-30 0001783875 us-gaap:CommonClassCMember 2022-06-30 0001783875 ffntf:ClassCMultipleVotingSharesMember 2022-06-30 0001783875 ffntf:HarvestedAndPurchasedCannabisMember 2022-06-30 0001783875 ffntf:UnharvestedCannabisMember 2022-06-30 0001783875 ffntf:CBDWellnessSegmentMember 2022-06-30 0001783875 ffntf:THCCannabisSegmentMember 2022-06-30 0001783875 ffntf:ManufacturedAndPurchasedExtractsMember 2022-06-30 0001783875 ffntf:RevenueMilestoneTwoMember srt:MaximumMember ffntf:OmOfMedicineMember 2022-06-30 0001783875 ffntf:WarrantExercisePriceZeroPointNineMember 2022-06-30 0001783875 ffntf:WarrantExercisePriceZeroPointSevenMember 2022-06-30 0001783875 ffntf:WarrantExercisePriceZeroPointEightTwoMember 2022-06-30 0001783875 ffntf:WarrantExercisePriceZeroPointSixSevenMember 2022-06-30 0001783875 ffntf:WarrantExercisePriceOneMember 2022-06-30 0001783875 ffntf:WarrantExercisePriceZeroPointEightZeroMember 2022-06-30 0001783875 ffntf:WarrantExercisePriceZeroPointEightZero2Member 2022-06-30 0001783875 ffntf:LILendingLLCMember ffntf:MahaConsultingLlcMember 2022-06-30 0001783875 us-gaap:ConvertibleDebtMember ffntf:HealthyPharmsIncMember 2022-06-30 0001783875 us-gaap:UnsecuredDebtMember ffntf:HealthyPharmsIncMember 2022-06-30 0001783875 ffntf:NewEnglandCannabisCorporationMember us-gaap:NotesPayableOtherPayablesMember 2022-06-30 0001783875 ffntf:ArkansasEntitiesMember us-gaap:UnsecuredDebtMember ffntf:FourteenPercentUnsecuredPromissoryNoteMember 2022-06-30 0001783875 ffntf:OtherMember 2022-06-30 0001783875 ffntf:IslandGlobalHoldingsInc.Member us-gaap:NotesPayableOtherPayablesMember 2022-06-30 0001783875 ffntf:EquipmentLoansMember us-gaap:SecuredDebtMember 2022-06-30 0001783875 ffntf:OmOfMedicineLLCMember ffntf:PromissoryNoteMember ffntf:TwelvePercentPromissoryNoteMember 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnJulyThirtyOneTwoThousandNineteenOneMember 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnJulyThirtyOneTwoThousandNineteenTwoMember 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnJulyThirtyOneTwoThousandNineteenThreeMember ffntf:EquityIncentivePlanMember 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnJulyThirtyOneTwoThousandNineteenFourMember 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnJulyThirtyOneTwoThousandNineteenFiveMember ffntf:EquityIncentivePlanMember 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnAugustTwentyTwoTwoThousandNineteenOneMember 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnAugustTwentyTwoTwoThousandNineteenTwoMember 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnNovemberOneTwoThousandNineteenMember ffntf:EquityIncentivePlanMember 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnFebruaryThreeTwoThousandTwentyMember ffntf:EquityIncentivePlanMember 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnJuneEightTwoThousandTwentyMember ffntf:EquityIncentivePlanMember 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnJulyThirtyOneTwoThousandTwentyMember ffntf:EquityIncentivePlanMember 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnSeptemberFifteenTwoThousandTwentyMember 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnOctoberTwoTwoThousandTwentyMember ffntf:EquityIncentivePlanMember 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnNovemberTwentyFourTwoThousandTwentyMember 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnDecemberTwoTwoThousandTwentyMember 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnDecemberTwentyOneThousandTwentyMember ffntf:EquityIncentivePlanMember 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnMarchEighteenTwoThousandTwentyOneMember ffntf:EquityIncentivePlanMember 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnAprilTwoTwoThousandTwentyOneMember ffntf:EquityIncentivePlanMember 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnAprilTwentyOneTwoThousandTwentyOneMember 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnJuneTwentyThreeTwoThousandTwentyOneMember ffntf:EquityIncentivePlanMember 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnNovemberElevenTwoThousandAndTwentyOneMember 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnJanuaryTwentyFiveTwoThousandAndTwentyTwoMember ffntf:EquityIncentivePlanMember 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnFebruaryOneTwoThousandAndTwentyTwoMember ffntf:EquityIncentivePlanMember 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnFebruarySeventeenTwoThousandAndTwentyTwoMember ffntf:EquityIncentivePlanMember 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnMarchOneTwoThousandAndTwentyTwoMember ffntf:EquityIncentivePlanMember 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnAprilTwentySevenTwoThousandTwentyTwoMember ffntf:EquityIncentivePlanMember 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnJuneSeventeenTwoThousandTwentyTwoMember ffntf:EquityIncentivePlanMember 2022-06-30 0001783875 ffntf:ArkansasEntitiesMember us-gaap:UnsecuredDebtMember 2022-06-30 0001783875 ffntf:OctoberTwoThousandAndTwentyOneConvertibleNoteMember 2022-06-30 0001783875 ffntf:OtherLoansMember 2022-06-30 0001783875 us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputSharePriceMember 2022-06-30 0001783875 us-gaap:MeasurementInputOptionVolatilityMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-06-30 0001783875 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-06-30 0001783875 us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputDiscountRateMember 2022-06-30 0001783875 ffntf:MeasurementInputExchangeRateMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-06-30 0001783875 us-gaap:PrivatePlacementMember 2022-06-30 0001783875 ffntf:LILendingLLCMember 2022-06-30 0001783875 us-gaap:LandMember 2022-06-30 0001783875 us-gaap:BuildingAndBuildingImprovementsMember 2022-06-30 0001783875 us-gaap:ConstructionInProgressMember 2022-06-30 0001783875 ffntf:FurnitureEquipmentAndOtherMember 2022-06-30 0001783875 us-gaap:LeaseholdImprovementsMember 2022-06-30 0001783875 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2022-06-30 0001783875 ffntf:ConvertibleNotesNotesPayableAndAccruedInterestMember 2022-06-30 0001783875 ffntf:ConstructionFinanceLiabilityMember 2022-06-30 0001783875 ffntf:ContingentConsiderationPayableMember 2022-06-30 0001783875 srt:MinimumMember 2022-06-30 0001783875 srt:MaximumMember 2022-06-30 0001783875 ffntf:MayTwoThousandTwentyConvertibleDebtMember 2022-06-30 0001783875 ffntf:TwoThousandTwentyTwoIslandGlobalHoldingsRelatedPartyNotesMember 2022-06-30 0001783875 ffntf:MayTwoThousandTwentyConvertibleNotesSwapsMember 2022-06-30 0001783875 us-gaap:FairValueInputsLevel1Member 2022-06-30 0001783875 us-gaap:FairValueInputsLevel2Member 2022-06-30 0001783875 us-gaap:FairValueInputsLevel3Member 2022-06-30 0001783875 ffntf:NewEnglandCannabisCorporationAcquisitionMember 2022-06-30 0001783875 ffntf:IslandGlobalHoldingsInc.Member 2022-06-30 0001783875 us-gaap:CorporateNonSegmentMember 2022-06-30 0001783875 ffntf:NomineeAgreementMember ffntf:MpIllinoisMember 2022-06-30 0001783875 ffntf:AccruesInterestMember 2022-06-30 0001783875 ffntf:OmOfMedicineMember 2021-12-31 0001783875 ffntf:HarvestedAndPurchasedCannabisMember 2021-12-31 0001783875 ffntf:UnharvestedCannabisMember 2021-12-31 0001783875 ffntf:CBDWellnessSegmentMember 2021-12-31 0001783875 ffntf:THCCannabisSegmentMember 2021-12-31 0001783875 ffntf:ManufacturedAndPurchasedExtractsMember 2021-12-31 0001783875 ffntf:LILendingLLCMember 2021-12-31 0001783875 ffntf:HealthyPharmsIncMember us-gaap:ConvertibleDebtMember 2021-12-31 0001783875 us-gaap:UnsecuredDebtMember ffntf:HealthyPharmsIncMember 2021-12-31 0001783875 ffntf:ArkansasEntitiesMember us-gaap:UnsecuredDebtMember ffntf:FourteenPercentUnsecuredPromissoryNoteMember 2021-12-31 0001783875 ffntf:OtherMember 2021-12-31 0001783875 ffntf:IslandGlobalHoldingsInc.Member us-gaap:NotesPayableOtherPayablesMember 2021-12-31 0001783875 ffntf:NewEnglandCannabisCorporationMember us-gaap:NotesPayableOtherPayablesMember 2021-12-31 0001783875 ffntf:EquipmentLoansMember us-gaap:SecuredDebtMember 2021-12-31 0001783875 ffntf:OmOfMedicineLLCMember ffntf:PromissoryNoteMember ffntf:TwelvePercentPromissoryNoteMember 2021-12-31 0001783875 ffntf:ArkansasEntitiesMember us-gaap:UnsecuredDebtMember 2021-12-31 0001783875 us-gaap:LandMember 2021-12-31 0001783875 us-gaap:BuildingAndBuildingImprovementsMember 2021-12-31 0001783875 us-gaap:ConstructionInProgressMember 2021-12-31 0001783875 ffntf:FurnitureEquipmentAndOtherMember 2021-12-31 0001783875 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001783875 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001783875 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001783875 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001783875 us-gaap:CorporateNonSegmentMember 2021-12-31 0001783875 ffntf:THCCannabisSegmentMember 2022-04-01 2022-06-30 0001783875 ffntf:CBDWellnessSegmentMember 2022-04-01 2022-06-30 0001783875 us-gaap:CorporateNonSegmentMember 2022-04-01 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember 2022-04-01 2022-06-30 0001783875 ffntf:ELMABuildingMember 2022-04-01 2022-06-30 0001783875 ffntf:OlympiaBuildingMember 2022-04-01 2022-06-30 0001783875 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001783875 us-gaap:ParentMember 2022-04-01 2022-06-30 0001783875 us-gaap:CapitalUnitsMember 2022-04-01 2022-06-30 0001783875 us-gaap:CostOfSalesMember 2022-04-01 2022-06-30 0001783875 ffntf:LILendingLLCMember 2022-04-01 2022-06-30 0001783875 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001783875 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001783875 ffntf:ReportedNewEnglandCannabisCorporationAcquisitionAndIslandGlobalHoldingsIncMember 2022-04-01 2022-06-30 0001783875 ffntf:ProformaNewEnglandCannabisCorporationAcquisitionAndIslandGlobalHoldingsIncMember 2022-04-01 2022-06-30 0001783875 ffntf:THCCannabisSegmentMember 2021-04-01 2021-06-30 0001783875 ffntf:CBDWellnessSegmentMember 2021-04-01 2021-06-30 0001783875 us-gaap:CorporateNonSegmentMember 2021-04-01 2021-06-30 0001783875 ffntf:EquityIncentivePlanMember 2021-04-01 2021-06-30 0001783875 ffntf:ELMABuildingMember 2021-04-01 2021-06-30 0001783875 ffntf:OlympiaBuildingMember 2021-04-01 2021-06-30 0001783875 ffntf:PureRatiosMember ffntf:OnlineCBDMarketMember 2021-04-01 2021-06-30 0001783875 us-gaap:CapitalUnitsMember ffntf:OmOfMedicineLLCMember 2021-04-01 2021-06-30 0001783875 us-gaap:ParentMember ffntf:OmOfMedicineLLCMember 2021-04-01 2021-06-30 0001783875 ffntf:OmOfMedicineLLCMember 2021-04-01 2021-06-30 0001783875 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001783875 us-gaap:ParentMember 2021-04-01 2021-06-30 0001783875 us-gaap:CapitalUnitsMember 2021-04-01 2021-06-30 0001783875 us-gaap:CostOfSalesMember 2021-04-01 2021-06-30 0001783875 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001783875 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001783875 ffntf:ReportedNewEnglandCannabisCorporationAcquisitionAndIslandGlobalHoldingsIncMember 2021-04-01 2021-06-30 0001783875 ffntf:ProformaNewEnglandCannabisCorporationAcquisitionAndIslandGlobalHoldingsIncMember 2021-04-01 2021-06-30 0001783875 us-gaap:CapitalUnitsMember 2021-01-01 2021-03-31 0001783875 us-gaap:ParentMember 2021-01-01 2021-03-31 0001783875 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001783875 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001783875 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001783875 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001783875 us-gaap:ParentMember 2022-01-01 2022-03-31 0001783875 us-gaap:CapitalUnitsMember 2022-01-01 2022-03-31 0001783875 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001783875 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001783875 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-06-30 0001783875 ffntf:CBDWellnessSegmentMember 2021-01-01 2021-06-30 0001783875 ffntf:THCCannabisSegmentMember 2021-01-01 2021-06-30 0001783875 ffntf:FourFrontHoldingsLLCMember ffntf:EquityBasedCompensationOptionsMember 2021-01-01 2021-06-30 0001783875 ffntf:EquityIncentivePlanMember 2021-01-01 2021-06-30 0001783875 srt:MinimumMember 2021-01-01 2021-06-30 0001783875 srt:MaximumMember 2021-01-01 2021-06-30 0001783875 ffntf:ELMABuildingMember 2021-01-01 2021-06-30 0001783875 ffntf:OlympiaBuildingMember 2021-01-01 2021-06-30 0001783875 ffntf:PureRatiosMember ffntf:OnlineCBDMarketMember 2021-01-01 2021-06-30 0001783875 us-gaap:CostOfSalesMember 2021-01-01 2021-06-30 0001783875 ffntf:IslandGlobalHoldingsInc.Member 2021-01-01 2021-06-30 0001783875 ffntf:ReportedNewEnglandCannabisCorporationAcquisitionAndIslandGlobalHoldingsIncMember 2021-01-01 2021-06-30 0001783875 ffntf:ProformaNewEnglandCannabisCorporationAcquisitionAndIslandGlobalHoldingsIncMember 2021-01-01 2021-06-30 0001783875 us-gaap:DomesticCountryMember 2022-01-01 2022-06-30 0001783875 us-gaap:StateAndLocalJurisdictionMember 2022-01-01 2022-06-30 0001783875 stpr:MA 2022-01-01 2022-06-30 0001783875 stpr:IL 2022-01-01 2022-06-30 0001783875 ffntf:EquityBasedCompensationOptionsMember ffntf:FourFrontHoldingsLLCMember 2022-01-01 2022-06-30 0001783875 ffntf:NewEnglandCannabisCorporationAnd29EverettAcquisitionMember 2022-01-01 2022-06-30 0001783875 ffntf:FourFrontHoldingsLLCMember 2022-01-01 2022-06-30 0001783875 ffntf:OmOfMedicineMember 2022-01-01 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:ClassAStockOptionsMember 2022-01-01 2022-06-30 0001783875 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-06-30 0001783875 ffntf:CBDWellnessSegmentMember 2022-01-01 2022-06-30 0001783875 ffntf:THCCannabisSegmentMember 2022-01-01 2022-06-30 0001783875 ffntf:RevenueMilestoneTwoMember ffntf:OmOfMedicineMember srt:MinimumMember 2022-01-01 2022-06-30 0001783875 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-06-30 0001783875 us-gaap:TradeSecretsMember 2022-01-01 2022-06-30 0001783875 us-gaap:TrademarksMember 2022-01-01 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:LILendingLLCMember 2022-01-01 2022-06-30 0001783875 ffntf:OctoberTwoThousandAndTwentyOneConvertibleNoteMember 2022-01-01 2022-06-30 0001783875 ffntf:OtherLoansMember 2022-01-01 2022-06-30 0001783875 ffntf:TwoThousandTwentyTwoIslandGlobalHoldingsRelatedPartyNotesMember 2022-01-01 2022-06-30 0001783875 ffntf:HealthyPharmsIncMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-06-30 0001783875 ffntf:IslandGlobalHoldingsInc.Member us-gaap:NotesPayableOtherPayablesMember 2022-01-01 2022-06-30 0001783875 ffntf:HealthyPharmsIncMember us-gaap:UnsecuredDebtMember 2022-01-01 2022-06-30 0001783875 us-gaap:NotesPayableOtherPayablesMember ffntf:NewEnglandCannabisCorporationMember 2022-01-01 2022-06-30 0001783875 ffntf:OtherMember 2022-01-01 2022-06-30 0001783875 us-gaap:SecuredDebtMember ffntf:EquipmentLoansMember 2022-01-01 2022-06-30 0001783875 ffntf:FourteenPercentUnsecuredPromissoryNoteMember ffntf:ArkansasEntitiesMember us-gaap:UnsecuredDebtMember 2022-01-01 2022-06-30 0001783875 ffntf:OmOfMedicineLLCMember ffntf:PromissoryNoteMember ffntf:TwelvePercentPromissoryNoteMember 2022-01-01 2022-06-30 0001783875 srt:MaximumMember 2022-01-01 2022-06-30 0001783875 srt:MinimumMember 2022-01-01 2022-06-30 0001783875 ffntf:LicensesMember 2022-01-01 2022-06-30 0001783875 ffntf:ELMABuildingMember 2022-01-01 2022-06-30 0001783875 ffntf:OlympiaBuildingMember 2022-01-01 2022-06-30 0001783875 ffntf:LicensesMember ffntf:IslandGlobalHoldingsIncMember 2022-01-01 2022-06-30 0001783875 us-gaap:TrademarksMember ffntf:IslandGlobalHoldingsIncMember 2022-01-01 2022-06-30 0001783875 ffntf:IslandGlobalHoldingsIncMember 2022-01-01 2022-06-30 0001783875 ffntf:ClassCMultipleVotingSharesMember 2022-01-01 2022-06-30 0001783875 ffntf:MayTwoThousandTwentyConvertibleDebtMember 2022-01-01 2022-06-30 0001783875 ffntf:MayTwoThousandTwentyConvertibleNotesSwapsMember 2022-01-01 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnJulyThirtyOneTwoThousandNineteenOneMember 2022-01-01 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnJulyThirtyOneTwoThousandNineteenTwoMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnJulyThirtyOneTwoThousandNineteenThreeMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnJulyThirtyOneTwoThousandNineteenFourMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnJulyThirtyOneTwoThousandNineteenFiveMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnAugustTwentyTwoTwoThousandNineteenOneMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnAugustTwentyTwoTwoThousandNineteenTwoMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnNovemberOneTwoThousandNineteenMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnFebruaryThreeTwoThousandTwentyMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnJuneEightTwoThousandTwentyMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnJulyThirtyOneTwoThousandTwentyMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnSeptemberFifteenTwoThousandTwentyMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnOctoberTwoTwoThousandTwentyMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnNovemberTwentyFourTwoThousandTwentyMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnDecemberTwoTwoThousandTwentyMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnDecemberTwentyOneThousandTwentyMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnMarchEighteenTwoThousandTwentyOneMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnAprilTwoTwoThousandTwentyOneMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnAprilTwentyOneTwoThousandTwentyOneMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnJuneTwentyThreeTwoThousandTwentyOneMember 2022-01-01 2022-06-30 0001783875 ffntf:EquityIncentivePlanMember ffntf:StockOptionsGrantedOnNovemberElevenTwoThousandAndTwentyOneMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnJanuaryTwentyFiveTwoThousandAndTwentyTwoMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnFebruaryOneTwoThousandAndTwentyTwoMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnFebruarySeventeenTwoThousandAndTwentyTwoMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnMarchOneTwoThousandAndTwentyTwoMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnAprilTwentySevenTwoThousandTwentyTwoMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 ffntf:StockOptionsGrantedOnJuneSeventeenTwoThousandTwentyTwoMember ffntf:EquityIncentivePlanMember 2022-01-01 2022-06-30 0001783875 us-gaap:CostOfSalesMember 2022-01-01 2022-06-30 0001783875 ffntf:ClassASubordinateVotingShareMember 2022-01-01 2022-06-30 0001783875 dei:AdrMember 2022-01-01 2022-06-30 0001783875 ffntf:NewEnglandCannabisCorporationAcquisitionMember 2022-01-01 2022-06-30 0001783875 ffntf:IslandGlobalHoldingsInc.Member 2022-01-01 2022-06-30 0001783875 ffntf:ClassASubordinateVotingSharesMember 2022-01-01 2022-06-30 0001783875 ffntf:ReportedNewEnglandCannabisCorporationAcquisitionAndIslandGlobalHoldingsIncMember 2022-01-01 2022-06-30 0001783875 ffntf:ProformaNewEnglandCannabisCorporationAcquisitionAndIslandGlobalHoldingsIncMember 2022-01-01 2022-06-30 0001783875 ffntf:NewEnglandCannabisCorporationMember 2022-01-01 2022-06-30 0001783875 ffntf:PurchaseAgreementMember ffntf:NewEnglandCannabisCorporationMember 2022-01-28 0001783875 ffntf:NewEnglandCannabisCorporationAnd29EverettAcquisitionMember 2022-01-28 0001783875 ffntf:ConvertibleDebtOneIssuedMember ffntf:BusinessAcquistionFirstAmendmentAgreementMember ffntf:NewEnglandCannabisCorporationMember 2022-01-28 0001783875 ffntf:NewEnglandCannabisCorporationMember 2022-01-28 0001783875 ffntf:EquityBasedCompensationOptionsMember ffntf:FourFrontHoldingsLLCMember 2021-01-01 2021-12-31 0001783875 ffntf:RevenueMilestoneOneMember ffntf:OmOfMedicineMember srt:MinimumMember 2021-01-01 2021-12-31 0001783875 us-gaap:CustomerRelationshipsMember 2021-01-01 2021-12-31 0001783875 us-gaap:NoncompeteAgreementsMember 2021-01-01 2021-12-31 0001783875 us-gaap:TradeSecretsMember 2021-01-01 2021-12-31 0001783875 us-gaap:TrademarksMember 2021-01-01 2021-12-31 0001783875 ffntf:LILendingLLCMember 2021-01-01 2021-12-31 0001783875 ffntf:TwoThousandTwentyTwoIslandGlobalHoldingsRelatedPartyNotesMember 2021-01-01 2021-12-31 0001783875 ffntf:MayTwoThousandTwentyConvertibleNotesSwapsMember 2021-01-01 2021-12-31 0001783875 ffntf:OctoberTwoThousandAndTwentyOneConvertibleNoteMember 2021-01-01 2021-12-31 0001783875 ffntf:OtherLoansMember 2021-01-01 2021-12-31 0001783875 ffntf:HealthyPharmsIncMember us-gaap:ConvertibleDebtMember 2021-01-01 2021-12-31 0001783875 us-gaap:UnsecuredDebtMember ffntf:HealthyPharmsIncMember 2021-01-01 2021-12-31 0001783875 us-gaap:NotesPayableOtherPayablesMember ffntf:IslandGlobalHoldingsInc.Member 2021-01-01 2021-12-31 0001783875 us-gaap:SecuredDebtMember ffntf:EquipmentLoansMember 2021-01-01 2021-12-31 0001783875 ffntf:MayTwoThousandTwentyConvertibleDebtMember 2021-01-01 2021-12-31 0001783875 ffntf:ClassASubordinateVotingSharesMember 2021-01-01 2021-12-31 0001783875 ffntf:ClassCMultipleVotingSharesMember 2021-01-01 2021-12-31 0001783875 ffntf:LILendingLLCMember 2022-01-28 2022-01-28 0001783875 ffntf:IslandGlobalHoldingsInc.Member 2022-01-28 2022-01-28 0001783875 ffntf:NewEnglandCannabisCorporationAnd29EverettAcquisitionMember 2022-01-28 2022-01-28 0001783875 ffntf:NewEnglandCannabisCorporationMember 2022-01-28 2022-01-28 0001783875 ffntf:BusinessAcquistionFirstAmendmentAgreementMember ffntf:NewEnglandCannabisCorporationMember 2022-01-28 2022-01-28 0001783875 ffntf:NewEnglandCannabisCorporationMember ffntf:SubordinateVotingShareMember 2022-01-28 2022-01-28 0001783875 ffntf:ConvertibleDebtOneIssuedMember ffntf:BusinessAcquistionFirstAmendmentAgreementMember ffntf:NewEnglandCannabisCorporationMember 2022-01-28 2022-01-28 0001783875 us-gaap:ConvertibleDebtMember 2020-05-14 2020-05-14 0001783875 us-gaap:ConvertibleDebtMember 2020-05-14 0001783875 ffntf:ConvertibleNotesSwapsMember 2020-05-28 2020-05-28 0001783875 ffntf:ConvertibleNotesSwapsMember 2020-05-28 0001783875 ffntf:OctoberTwoThousandAndTwentyOneConvertibleNoteMember 2021-10-06 2021-10-06 0001783875 ffntf:OctoberTwoThousandAndTwentyOneConvertibleNoteMember 2021-10-06 0001783875 ffntf:LILendingLLCMember 2019-05-10 0001783875 ffntf:LILendingLLCMember 2019-01-01 2019-12-31 0001783875 ffntf:LILendingLLCMember 2020-04-30 2020-04-30 0001783875 ffntf:LILendingLLCMember 2020-04-30 0001783875 ffntf:LILendingLLCMember 2020-01-01 2020-12-31 0001783875 ffntf:LILendingLLCMember 2020-12-31 0001783875 ffntf:LILendingLLCMember 2022-01-01 2022-01-01 0001783875 ffntf:LILendingLLCMember 2022-01-01 0001783875 ffntf:CapitalUnitsOneMember us-gaap:PrivatePlacementMember 2020-11-23 2020-11-23 0001783875 us-gaap:PrivatePlacementMember 2020-11-23 2020-11-23 0001783875 ffntf:CapitalUnitsOneMember us-gaap:PrivatePlacementMember 2020-11-23 0001783875 us-gaap:PrivatePlacementMember 2020-11-23 0001783875 us-gaap:ValuationTechniqueOptionPricingModelMember 2020-11-23 0001783875 us-gaap:MeasurementInputExercisePriceMember us-gaap:ValuationTechniqueOptionPricingModelMember 2020-11-23 0001783875 us-gaap:MeasurementInputOptionVolatilityMember us-gaap:ValuationTechniqueOptionPricingModelMember 2020-11-23 0001783875 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:ValuationTechniqueOptionPricingModelMember 2020-11-23 0001783875 us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputDiscountRateMember 2020-11-23 0001783875 ffntf:MeasurementInputExchangeRateMember us-gaap:ValuationTechniqueOptionPricingModelMember 2020-11-23 0001783875 ffntf:IslandGlobalHoldingsInc.Member 2022-04-25 0001783875 ffntf:SubordinateVotingShareMember ffntf:NewEnglandCannabisCorporationMember ffntf:MergerAgreementMember 2022-04-25 0001783875 ffntf:MergerAgreementMember us-gaap:LetterOfCreditMember 2022-04-25 0001783875 ffntf:IslandGlobalHoldingsInc.Member 2022-04-25 2022-04-25 0001783875 us-gaap:TrademarksMember 2022-04-25 2022-04-25 0001783875 us-gaap:GoodwillMember 2022-04-25 2022-04-25 0001783875 ffntf:SubordinateVotingShareMember ffntf:NewEnglandCannabisCorporationMember ffntf:MergerAgreementMember 2022-04-25 2022-04-25 0001783875 ffntf:SubordinateVotingShareMember ffntf:MergerAgreementMember 2022-04-25 2022-04-25 0001783875 us-gaap:SubsequentEventMember ffntf:PromissoryNoteMember 2022-07-01 2022-07-31 0001783875 ffntf:SellerNoteMember us-gaap:SubsequentEventMember 2022-07-01 2022-07-31 0001783875 ffntf:SellerNoteMember us-gaap:SubsequentEventMember 2022-07-31 0001783875 ffntf:SellerNoteMember 2022-04-01 2022-04-30 0001783875 us-gaap:CapitalUnitsMember 2022-06-30 0001783875 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001783875 us-gaap:RetainedEarningsMember 2022-06-30 0001783875 us-gaap:ParentMember 2022-06-30 0001783875 us-gaap:NoncontrollingInterestMember 2022-06-30 0001783875 us-gaap:CapitalUnitsMember 2021-06-30 0001783875 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001783875 us-gaap:RetainedEarningsMember 2021-06-30 0001783875 us-gaap:ParentMember 2021-06-30 0001783875 us-gaap:NoncontrollingInterestMember 2021-06-30 0001783875 us-gaap:CapitalUnitsMember 2020-12-31 0001783875 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001783875 us-gaap:RetainedEarningsMember 2020-12-31 0001783875 us-gaap:ParentMember 2020-12-31 0001783875 us-gaap:NoncontrollingInterestMember 2020-12-31 0001783875 us-gaap:CapitalUnitsMember 2021-03-31 0001783875 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001783875 us-gaap:RetainedEarningsMember 2021-03-31 0001783875 us-gaap:ParentMember 2021-03-31 0001783875 us-gaap:NoncontrollingInterestMember 2021-03-31 0001783875 us-gaap:NoncontrollingInterestMember 2021-12-31 0001783875 us-gaap:ParentMember 2021-12-31 0001783875 us-gaap:RetainedEarningsMember 2021-12-31 0001783875 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001783875 us-gaap:CapitalUnitsMember 2021-12-31 0001783875 us-gaap:CapitalUnitsMember 2022-03-31 0001783875 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001783875 us-gaap:RetainedEarningsMember 2022-03-31 0001783875 us-gaap:ParentMember 2022-03-31 0001783875 us-gaap:NoncontrollingInterestMember 2022-03-31 0001783875 ffntf:LicensesMember 2022-06-30 0001783875 us-gaap:CustomerRelationshipsMember 2022-06-30 0001783875 us-gaap:NoncompeteAgreementsMember 2022-06-30 0001783875 us-gaap:TradeSecretsMember 2022-06-30 0001783875 us-gaap:TrademarksMember 2022-06-30 0001783875 ffntf:LicensesMember 2020-12-31 0001783875 us-gaap:CustomerRelationshipsMember 2020-12-31 0001783875 us-gaap:NoncompeteAgreementsMember 2020-12-31 0001783875 us-gaap:TradeSecretsMember 2020-12-31 0001783875 us-gaap:TrademarksMember 2020-12-31 0001783875 ffntf:MayTwoThousandTwentyConvertibleDebtMember 2020-12-31 0001783875 ffntf:TwoThousandTwentyTwoIslandGlobalHoldingsRelatedPartyNotesMember 2020-12-31 0001783875 ffntf:OtherLoansMember 2020-12-31 0001783875 ffntf:MayTwoThousandTwentyConvertibleNotesSwapsMember 2020-12-31 0001783875 ffntf:MayTwoThousandTwentyConvertibleDebtMember 2021-12-31 0001783875 ffntf:TwoThousandTwentyTwoIslandGlobalHoldingsRelatedPartyNotesMember 2021-12-31 0001783875 ffntf:MayTwoThousandTwentyConvertibleNotesSwapsMember 2021-12-31 0001783875 ffntf:OctoberTwoThousandAndTwentyOneConvertibleNoteMember 2021-12-31 0001783875 ffntf:OtherLoansMember 2021-12-31 0001783875 ffntf:ClassASubordinateVotingSharesMember 2020-12-31 0001783875 ffntf:ClassCMultipleVotingSharesMember 2020-12-31 0001783875 ffntf:ClassASubordinateVotingSharesMember 2021-12-31 0001783875 ffntf:ClassCMultipleVotingSharesMember 2021-12-31 0001783875 ffntf:LicensesMember 2021-12-31 0001783875 us-gaap:CustomerRelationshipsMember 2021-12-31 0001783875 us-gaap:NoncompeteAgreementsMember 2021-12-31 0001783875 us-gaap:TradeSecretsMember 2021-12-31 0001783875 us-gaap:TrademarksMember 2021-12-31 iso4217:USD xbrli:shares xbrli:pure utr:Year utr:Month iso4217:CAD iso4217:USD xbrli:shares ffntf:Segment iso4217:CAD xbrli:shares
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
10-Q
 
 
(Mark One)
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: June 30, 2022
OR
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______________ to ______________
Commission File Number
000-56075
 
 
4Front Ventures Corp.
(Exact name of registrant as specified in its charter)
 
 
 
British Columbia
 
83-4168417
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer
Identification No.)
5060 N. 40th Street
Suite 120
Phoenix, Arizona 85018
(Address of principal executive offices
and
zip code)
 
 
Registrant’s telephone number, including area code: (602)
633-3067
Securities registered pursuant to Section 12(b) of the Act:
 
Title of Each Class
 
Trading
Symbol(s)
 
Name of Each Exchange
on Which Registered
Class A Subordinate Voting Shares, no par value
 
FFNTF
 
OTCQX
   
FFNT
 
CSE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(Section 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act:
 
Large accelerated filer
 
  
Accelerated filer
 
       
Non-accelerated
filer
 
  
Smaller reporting company
 
       
        
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act).    Yes  ☐    No  
As of August
15
, 2022, the registrant had 636,636,686 Class A subordinate voting shares outstanding.
 
 
 

4Front Ventures Corp.
FORM
10-Q
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022
TABLE OF CONTENTS
 
 
 
 
  
Page
 
PART I.
 
  
     
     
Item 1.
 
  
     
 
 
  
 
1
 
 
 
  
 
2
 
 
 
  
 
3
 
 
 
  
 
5
 
 
 
  
 
6
 
Item 2.
 
  
 
29
 
Item 3.
 
  
 
38
 
Item 4.
 
  
 
38
 
     
PART II.
 
  
     
     
Item 1.
 
  
 
40
 
Item 1A.
 
  
 
40
 
Item 2.
 
  
 
41
 
Item 3.
 
  
 
41
 
Item 4.
 
  
 
41
 
Item 5.
 
  
 
41
 
Item 6.
 
  
 
42
 
  
 
43
 
 
 
i

PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (unaudited)
As of June 30, 2022 and December 31, 2021
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
 
  
June 30, 2022
 
 
December 31, 2021
 
 
  
 
 
 
 
 
ASSETS
                
Current assets:
                
Cash
   $ 6,032     $ 22,581  
Accounts receivable, net
     5,844       1,946  
Other receivables
     33       289  
Current portion of lease receivables
     3,405       3,630  
Inventory
     28,837       20,087  
Current portion of notes receivable
              109  
Prepaid expenses
     2,974       2,232  
    
 
 
   
 
 
 
Total current assets
     47,125       50,874  
    
 
 
   
 
 
 
Property, plant, and equipment, net
     58,967       42,633  
Lease receivables
     6,541       6,748  
Intangible assets, net
     54,239       26,246  
Goodwill
     42,037       23,155  
Right-of-use
assets
     106,406       100,519  
Deposits
     5,142       5,364  
    
 
 
   
 
 
 
TOTAL ASSETS
   $ 320,457     $ 255,539  
    
 
 
   
 
 
 
LIABILITIES AND SHAREHOLDERS’ EQUITY
                
LIABILITIES
                
Current liabilities:
                
Accounts payable
   $ 6,391     $ 2,131  
Accrued expenses and other current liabilities
     13,031       9,411  
Taxes payable
     29,651       23,968  
Derivative liability
     428       3,502  
Current portion of contract liabilities
     1,535           
Current portion of convertible notes
              2,784  
Current portion of lease liability
     4,121       3,629  
Current portion of notes payable and accrued interest
     8,235       3,413  
    
 
 
   
 
 
 
Total current liabilities
     63,392       48,838  
    
 
 
   
 
 
 
Convertible notes
     15,205       14,641  
Notes payable and accrued interest from related party
     49,366       48,266  
Long term notes payable
     10,128       1,709  
Long term accounts payable
     1,200       1,200  
Contract liabilities
     2,000           
Contingent consideration payable
              2,393  
Construction finance liability
     16,000           
Deferred tax liability
     6,884       7,849  
Lease liability
     101,380       93,111  
    
 
 
   
 
 
 
TOTAL LIABILITIES
     265,555       218,007  
    
 
 
   
 
 
 
SHAREHOLDERS’ EQUITY
                
Equity attributable to 4Front Ventures Corp.
     302,502       274,120  
Additional
paid-in
capital
     53,625       52,197  
Deficit
     (301,307     (288,857
Non-controlling
interest
     82       72  
    
 
 
   
 
 
 
TOTAL SHAREHOLDERS’ EQUITY
     54,902       37,532  
    
 
 
   
 
 
 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
   $ 320,457     $ 255,539  
    
 
 
   
 
 
 
See accompanying notes to financial statements.
 
1

4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS (unaudited)
For the Three and Six Months Ended June 30, 2022 and 2021
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
    
Three Months Ended June 30,
   
Six Months Ended June 30,
 
    
2022
   
2021
   
2022
   
2021
 
                          
REVENUE
                                
Revenue from sale of goods
   $ 25,488     $ 24,452     $ 48,571     $ 44,532  
Real estate income
     2,951       2,669       5,916       5,559  
    
 
 
   
 
 
   
 
 
   
 
 
 
Total revenues
     28,439       27,121       54,487       50,091  
Cost of goods sold
     (16,123     (10,816     (28,717     (19,941
    
 
 
   
 
 
   
 
 
   
 
 
 
Gross profit
     12,316       16,305       25,770       30,150  
OPERATING EXPENSES
                                
Selling and marketing expenses
     6,327       6,714       11,493       11,871  
General and administrative expenses
     6,566       5,083       14,210       10,248  
Depreciation and amortization
     1,123       861       1,970       1,635  
Transaction and restructuring related expenses

 
 
2,009
 
 
 
 
 
 
2,009
 
 
 
 
Equity based compensation
     390       2,979       1,428       5,375  
    
 
 
   
 
 
   
 
 
   
 
 
 
Total operating expenses
     16,415       15,637       31,110       29,129  
    
 
 
   
 
 
   
 
 
   
 
 
 
(Loss) Income from operations
     (4,099 )     668       (5,340     1,021  
Other income (expense)
                                
Interest income
              8       2       11  
Interest expense
     (3,418     (2,901     (6,038     (5,362
Amortization of loan discount upon conversion of debt to equity
                                (2,915
Change in fair value of derivative liability
     1,774       (311     3,074       (2,843
Change in contingent consideration payable
     2,393                2,393           
Loss on lease termination
           (331           (1,210
Other
     (154              (51         
    
 
 
   
 
 
   
 
 
   
 
 
 
Total other income (expense), net

     595       (3,535     (620     (12,319
    
 
 
   
 
 
   
 
 
   
 
 
 
Net loss before income taxes
     (3,504     (2,867     (5,960     (11,298
Income tax expense
     (3,042     (3,351     (6,480     (6,004
Net loss
     (6,546     (6,218     (12,440     (17,302
Net income attributable to
non-controlling
interest
     5       5       10       10  
    
 
 
   
 
 
   
 
 
   
 
 
 
Net loss attributable to shareholders
   $ (6,551   $ (6,223   $ (12,450   $ (17,312
    
 
 
   
 
 
   
 
 
   
 
 
 
Basic and diluted loss per share
   $ (0.01   $ (0.01   $ (0.02   $ (0.03
Weighted average number of shares outstanding, basic and
diluted
     636,653,975       587,218,794       628,175,765       573,108,183  
See accompanying notes to condensed interim financial statements.
 
2

4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (unaudited)
For the Six Months Ended June 30, 2022 and 2021
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
    
Share Capital
                                  
    
Shares
    
Amount
    
Additional

Paid-In

Capital
    
Deficit
   
Total 4Front

Ventures Corp.

Shareholders’

Equity
   
Non-

Controlling

Interest
    
Total

Shareholders’

Equity
 
                                                
Balance, December 31, 2021
     594,181,604      $ 274,120      $ 52,197      $ (288,857   $ 37,460     $ 72      $ 37,532  
Shares issued for NECC pursuant to acquisition
     28,571,428        18,200        —          —         18,200       —          18,200  
Share-based compensation
     —          —          1,038        —         1,038       —          1,038  
Conversion of notes to equity
     6,235,512        3,122        —          —         3,122       —          3,122  
Shares issued with exercise of warrants
     88,659        50        —          —         50       —          50  
Net loss
     —          —          —          (5,899     (5,899     5        (5,894
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
    
 
 
 
Balance, March 31, 2022
     629,077,203      $ 295,492      $ 53,235      $ (294,756   $ 53,971     $ 77      $ 54,048  
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
    
 
 
 
Shares issued for Island pursuant to acquisition
     8,783,716        6,245        —          —         6,245       —          6,245  
Warrants issued for Island pursuant to acquisition
     —          732        —          —         732       —          732  
Share-based compensation
     —          —          390        —         390       —          390  
Shares issued with exercise of stock options
     51,975        33        —          —         33       —          33  
Net loss
     —          —          —          (6,551     (6,551     5        (6,546
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
    
 
 
 
Balance, June 30, 2022
     637,912,894      $ 302,502      $ 53,625      $ (301,307 )   $ 54,820     $ 82      $ 54,902  
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
    
 
 
 
See accompanying notes to condensed interim financial statements.
 
3

4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (unaudited)
For the Six Months Ended June 30, 2022 and 2021
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
    
Share Capital
                                  
    
Shares
   
Amount
    
Additional

Paid-In

Capital
    
Deficit
   
Total 4Front

Ventures Corp.

Shareholders’

Equity
   
Non-

Controlling

Interest
    
Total

Shareholders’

Equity
 
                                               
Balance, December 31, 2020
     538,851,252     $ 250,583      $ 42,116      $ (250,548   $ 42,151     $ 52      $ 42,203  
    
 
 
   
 
 
    
 
 
    
 
 
   
 
 
   
 
 
    
 
 
 
Shares issued for Pure Ratios earnout
     473,491       161        —          —         161       —          161  
Share-based compensation
     —         —          2,396        —         2,396       —          2,396  
Conversion of notes to equity
     24,366,003       6,253        —          —         6,253       —          6,253  
Shares issued with exercise of stock options
     1,358,116       871        —          —         871       —          871  
Shares issued with exercise of warrants
     2,422,363       1,563        —          —         1,563       —          1,563  
Return of treasury shares
     (8,320     —          —          —         —         —          —    
Net loss
     —                             (11,089     (11,089     5        (11,084
    
 
 
   
 
 
    
 
 
    
 
 
   
 
 
   
 
 
    
 
 
 
Balance, March 31, 2021
     567,462,905     $ 259,431      $ 44,512      $ (261,637   $ 42,306     $ 57      $ 42,363  
    
 
 
   
 
 
    
 
 
    
 
 
   
 
 
   
 
 
    
 
 
 
Shares issued for Om of Medicine earnout
     535,018       722        —          —         722       —          722  
Share-based compensation
     —         —          2,979        —         2,979       —          2,979  
Conversion of notes to equity
     24,676,794       11,466        —          —         11,466       —          11,466  
Shares issued with exercise of stock options
     652,940       443        —          —         443       —          443  
Shares issued with exercise of warrants
     570,864       1,813        —          —         1,813       —          1,813  
Net loss
     —         —          —          (6,223     (6,223     5        (6,218
    
 
 
   
 
 
    
 
 
    
 
 
   
 
 
   
 
 
    
 
 
 
Balance, June 30, 2021
     593,898,521     $ 273,875      $ 47,491      $ (267,860   $ 53,506     $ 62      $ 53,568  
    
 
 
   
 
 
    
 
 
    
 
 
   
 
 
   
 
 
    
 
 
 
See accompanying notes to condensed interim financial statements.
 
4

4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (unaudited)
For the Six Months Ended June 30, 2022 and 2021
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
    
Six Months Ended June 30,
 
    
2022
   
2021
 
              
CASH FLOWS FROM OPERATING ACTIVITIES
                
Net loss
   $ (12,440   $ (17,302
Adjustments to reconcile net loss to net cash used by operating activities
                
Depreciation and amortization
     4,689       2,166  
Equity based compensation
     1,428       5,375  
Change in fair value of derivative liability
     (3,074     2,843  
Change in fair value of contingent consideration
     (2,393         
Amortization of
right-of-use
assets
              1,765  
Accretion of lease liability
     2,803       (478
Write-off
of fixed asset from terminated lease
           1,210  
Accretion of contingent consideration
              228  
Accretion of convertible debenture and interest
     564       850  
Accrued interest on notes payable
     3,614       3,884  
Interest accrued - lease receivable
     432       349  
Deferred taxes
     (965     632  
Amortization of loan discount upon conversion of debt to equity
              2,915  
Changes in operating assets and liabilities
     2,458       (170
    
 
 
   
 
 
 
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES
     (2,884     4,267  
    
 
 
   
 
 
 
CASH FLOWS FROM INVESTING ACTIVITIES
                
Payment for NECC business combination, net of cash acquired
     (24,998         
Cash acquired as part of Island business combination
     458           
Notes receivable repayments
     109       405  
Sale of dispensaries and interests in cannabis licenses
              1,093  
Purchases of property and equipment
     (2,249     (12,234
    
 
 
   
 
 
 
NET CASH USED IN INVESTING ACTIVITIES
     (26,680     (10,736
    
 
 
   
 
 
 
CASH FLOWS FROM FINANCING ACTIVITIES
                
Payment of contingent consideration
     (412 )     (1,204
Proceeds from issuance of construction financing liability
     16,000           
Proceeds from the exercise of warrants
     50       1,664  
Proceeds from the exercise of stock options
     33       1,314  
Repayment of notes payable
     (2,656     (2,674
    
 
 
   
 
 
 
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES
     13,015       (900
    
 
 
   
 
 
 
NET DECREASE IN CASH
     (16,549     (7,369
CASH, BEGINNING OF QUARTER
     22,581       18,932  
    
 
 
   
 
 
 
CASH, END OF QUARTER
   $ 6,032     $ 11,563  
    
 
 
   
 
 
 
See accompanying notes to condensed interim financial statements.
 
5

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
Note 1: NATURE OF OPERATIONS
4Front Ventures Corp. (“4Front” or the “Company”) exists pursuant to the provisions of the British Columbia Corporations Act. On July 31, 2019, 4Front Holdings LLC (“Holdings”) completed a Reverse Takeover Transaction (“RTO”) with Cannex Capital Holdings Inc. (“Cannex”) whereby Holdings acquired Cannex and the shareholders of Holdings became the controlling shareholders of the Company. Following the RTO, the Company’s SVS are listed on the Canadian Securities Exchange (“CSE”) under the ticker “FFNT” and are quoted on the OTC (OTCQX: FFNTF).
The Company has two primary operating segments: THC Cannabis and CBD Wellness. With regard to its THC Cannabis segment, as of June 30, 2022, the Company operates six dispensaries in Massachusetts, Illinois, and Michigan, primarily under the “MISSION” brand name. As of June 30, 2022, the Company operates three
production facilities in Massachusetts, Illinois and California and produces the majority of products that are sold at its own Massachusetts and Illinois dispensaries. Also, as part of its THC Cannabis segment, the Company leases real estate and sells equipment, supplies, and intellectual property to cannabis producers in the state of Washington.
While marijuana is legal under the laws of several U.S. states (with varying restrictions), the United States Federal Controlled Substances Act classifies all “marijuana” as a Schedule 1 drug, whether for medical or recreational use. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision.
The Company’s CBD Wellness segment is focused upon its ownership and operation of its wholly owned subsidiary, Pure Ratios Holdings, Inc. (“Pure Ratios”), a
CBD-focused
wellness company in California, that sells
non-THC
hemp derived products throughout the United States.
On January 28, 2022, the Company entered into an agreement and plan of merger (the “NECC Merger Agreement”) with New England Cannabis Corporation, Inc., a Massachusetts Corporation (“NECC”) and a wholly owned subsidiary of the Company entered into an amended membership interest purchase agreement (the “Everett Purchase Agreement,” and together with the NECC Merger Agreement, the “NECC Merger Agreements”) with Kenneth Stevens to purchase all of the membership interests of 29 Everett, LLC (“29 Everett”), a Massachusetts limited liability company. See Note 7 for further details on the NECC Merger Agreements and corresponding transactions under such agreements.
On March 30, 2022, the Company entered into an agreement and plan of merger (the “Island Merger Agreement”) by and among the Company, Island Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Island Merger Sub”); Island Global Holdings, Inc., a California corporation (“Island”); and Navy Capital SR LLC, a Delaware limited liability company (“Navy”, and together with the Company, Island Merger Sub, and Island, the “Island Parties”). In April 2022, pursuant to the terms and conditions of the Merger Agreement, Island Merger Sub merged with and into Island, with Island surviving the merger and continuing its corporate existence as a wholly owned subsidiary of the Company (the “Island Merger”). See Note 7 for further details on the Island Merger Agreements and corresponding transactions under such agreements.
Management continues to evaluate the impact of the
COVID-19
pandemic on the Company’s industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position and results of its operations, the specific impact is not readily determinable as of the date of these consolidated financial statements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
The corporate office address of the Company is 5060 North 40th Street, Suite 120, Phoenix, Arizona, and the Company’s registered office is 550 Burrard Street, Suite 2900, Vancouver, British Columbia.
 
6

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
Note 2: BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted, pursuant to such rules and regulations.
In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2021, included in the Company’s Annual Report on Form
10-K,
filed April 18, 2022, with the U.S. Securities and Exchange Commission, as well as the Company’s Amendment to the Annual Report on Form
10-K,
filed April 21, 2022, and on the System for Electronic Document Analysis and Retrieval in Canada (or SEDAR). The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
There have been no changes to the Company’s significant accounting policies as described in Note 2 of the Company’s 2021 Annual Report on Form
10-K.
The Company’s accounting policies have remained consistent with those disclosed in the latest annual consolidated financial statements except for the additional policy noted below.
Principles of consolidation
The accompanying condensed consolidated interim financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation. The financial results of NECC are included in the condensed consolidated financial statements beginning on January 28, 2022, the merger closing date. The financial results of Island are included in the condensed consolidated financial statements beginning on April 25, 2022, the merger closing date.
The financial statements of the subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies.
Note 3: SIGNIFICANT ACCOUNTING POLICIES
 
(a)
Critical accounting estimates and judgments
Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of the Company’s condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. The significant judgments made by management in applying the Company’s accounting policies and the key sources of estimation uncertainty were the same as those described in the latest annual consolidated financial statements, except for additional accounting policies identified during the interim period noted below.
 
7

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
Contract Assets and Liabilities
To the extent that the customer has paid consideration before transferring goods or services to the customer, a contract liability is recorded on the consolidated balance sheet as current portion of contract liabilities for contract liabilities due within twelve months or contract liabilities for contract liabilities due after twelve months. When the Company has an unconditional right to payment, a receivable is recorded on the consolidated balance sheet as current portion of contract assets for contract assets due within twelve months or contract assets for contract assets due after twelve months. Amounts expected to be recognized as revenue within the twelve months following the balance sheet date are classified as current portion of contract liabilities in the accompanying condensed balance sheets. Amounts not expected to be recognized as revenue within the twelve months following the balance sheet date are classified as contract liabilities. The accompanying condensed balance sheets reflect a contract liability for the amount of revenue to be recognized in the future as and when the Company satisfies its remaining performance obligations. As of June 30, 2022, in connection with the Island Merger, the Company had recogn
ized $
3,535
of contract liabilities, $
1,535
of which were recorded as current liabilities and $
2,000
were recorded as long term liabilities. See Note 7 for further discussion on the Island Merger.
We cannot predict what future laws and regulations might be passed that could have a material effect on our results of operations. We assess the impact of significant changes in laws and regulations on a regular basis and update the assumptions and estimates used to prepare our financial statements when we deem it necessary.
 
(b)
Recent Accounting Pronouncements
Recently Adopted
 
  i.
In August 2020, the FASB issued ASU
2020-06,
“Debt – Debt with Conversion and Other Options (Subtopic
470-20)
and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic
815-40)”.
ASU
2020-06
simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU
2020-06
is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Adoption of this standard did not materially impact the Company’s consolidated financial position, results of operations or cash flows.
 
  ii.
In May 2021, the FASB issued ASU
2021-04,
“Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (Subtopic
815-40)”.
ASU
2021-04
clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU
2021-04
is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Adoption of this standard did not materially impact the Company’s consolidated financial position, results of operations or cash flows.
 
  iii.
In October 2021, the FASB issued ASU 2021-08, “Business Combinations—Accounting for Contract Assets and Contract Liabilities (Topic 805)”. The amendments in this update address diversity and inconsistency related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination by requiring that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. As a result of the amendments made by the ASU, it is expected than an acquirer will generally recognize and measure acquired contract assets and contract liabilities in a manner consistent with how the acquiree recognized and measured them in its pre-acquisition financial statements. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. An entity that early adopts in an interim period should apply the amendments (i) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (ii) prospectively to all business combinations that occur on or after the date of initial application. The Company has elected to early adopt this standard as of January 1, 2022. The adoption of the standard had an impact on the valuation of Island deferred revenue contracts upon the acquisition date. The Company recognized the contract liabilities acquired consistent with the previous accounting treatment at the acquired entity. This standard did not have an impact on the NECC acquisition entered into on January 28, 2022.
 
8

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
Accounting Pronouncements Not Yet Adopted
 
  i.
In June 2022, the FASB issued ASU
2022-03,
“Fair Value Measurements—Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (Topic 820)”. ASU
2022-03
clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. It also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. For public business entities, the ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted and the amendments in the ASU should be applied prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption. The Company is currently assessing the impact of adopting ASU
2022-03
on the consolidated financial statements.
Note 4: INVENTORY
The Company’s inventories include the following as of June 30, 2022 and December 31, 2021:
 
    
June 30, 2022
    
December 31, 2021
 
Raw materials - unharvested cannabis
   $ 2,849      $ 2,164  
Raw materials - harvested and purchased cannabis
     10,824        3,045  
Packaging and other
non-finished
goods
     2,986        1,734  
Work in process - manufactured and purchased extracts
     4,825        4,771  
Finished goods
     7,353        8,373  
    
 
 
    
 
 
 
Total
   $ 28,837      $ 20,087  
    
 
 
    
 
 
 
Note 5: PROPERTY, PLANT, AND EQUIPMENT
Property, plant and equipment and related depreciation are summarized in the table below:
 
    
June 30,
2022
    
December 31,
2021
 
Land
   $ 775      $     
Buildings & improvements
     13,896        1,483  
Construction in process
     702        63  
Furniture, equipment & other
     17,974        13,425  
Leasehold improvements
     36,878        35,538  
    
 
 
    
 
 
 
Total
   $ 70,225      $ 50,509  
Less: accumulated depreciation
     (11,258      (7,876
    
 
 
    
 
 
 
Total property, plant, and equipment, net
   $ 58,967      $ 42,633  
    
 
 
    
 
 
 
On January 28, 2022, in conjunction with a business combination with NECC, the Company acquired property, plant, and equipment totaling $15,238 (Note 7). The Company subsequently sold the property, plant, and equipment to a third-party and leased back the equipment from the third-party. As discussed in Note 9, the Company recognized this fact pattern as a failed sale-leaseback transaction, whereby the Company recognized the fixed assets on the balance sheet of NECC and established a construction finance liability for rental payments made as part of the lease agreement.
On April 25, 2022, in conjunction with a business combination with Island, the Company acquired property and equipment totaling $2,214. (Note 7).
Approximately $33,000 of property and equipment is secured by LI Lending as collateral on the LI Lending note (Note 9). There were no significant contractual commitments for future capital expenditures as of June 30, 2022 and December 31, 2021.
Depreciation of property, plant, and equipment is computed using the
 straight-line method over the asset’s estimated useful life. The Company does not depreciate land, which has an indefinite useful life. Depreciation expense for the six months ended June 30, 2022 and 2021 was $3,382 and $1,138, respectively, of which $2,719 and $725, respectively, is included in cost of goods sold. Depreciation expense for the three months ended June 30, 2022 and 2021 was $2,217 and $675, respectively, of which $1,771 and $400, respectively, is included in cost of goods sold.
 
9

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
Note 6: INTANGIBLE ASSETS AND GOODWILL
Intangible Assets
Intangible assets are recorded at cost less accumulated amortization and impairment losses. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization of definite life intangibles is recognized on a straight-line basis over their estimated useful lives. The estimated useful lives, residual values, and amortization methods are reviewed at each year end, and any changes in estimates are accounted for prospectively.
Intangible assets and related amortization are summarized in the table below:
 
    
Licenses
    
Customer
Relationships
   
Non-Competition

Agreements
   
Know-How
   
Tradenames
and
Trademarks
   
Total
 
Balance, December 31, 2020
   $ 20,146      $ 1,668     $ 43     $ 6,933     $        $ 28,790  
Amortization expense
     —          (580     (43     (1,921              (2,544
    
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balance, December 31, 2021
   $ 20,146      $ 1,088     $        $ 5,012     $        $ 26,246  
NECC merger and 29 Everett acquisition (Note 7)
     18,000        —         —         —         —         18,000  
Island merger (Note 7)
     8,700        —         —         —         2,600       11,300  
Amortization expense
     —          (290             (970     (47     (1,307
    
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balance, June 30, 2022
   $ 46,846      $ 798     $        $ 4,042     $ 2,553     $ 54,239  
    
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Goodwill
 
Balance, December 31, 2020
  
$
23,155
 
    
 
 
 
Balance, December 31, 2021
  
$
23,155
 
NECC merger and 29 Everett acquisition (Note 7)
     12,547  
Island merger (Note 7)
     6,335  
    
 
 
 
Balance, June 30, 2022
  
$
42,037
 
    
 
 
 
Impairment of Intangible Assets and Goodwill
On an annual basis, the Company assesses the Company’s reporting units (“RUs”) for indicators of impairment or when facts or circumstances suggest that it is more likely than not that the carrying amount may exceed fair value. For the purpose of impairment testing, goodwill is allocated to the Company’s RUs to which it relates.
Goodwill was not tested for impairment during the six months ended June 30, 2022.
Six Months Ended June 30, 2022
On January 28, 2022, the Company entered into the NECC Merger Agreements with NECC and 29 Everett for total consideration of $45,200. As part of the purchase price allocation of the acquisition and merger, the Company recognized $18,000 of acquired licenses and $12,547 of goodwill based on the consideration transferred and fair value of
net
assets acquired.
On April 25, 2022, the Company entered into the Island Merger Agreement with Island for total consideration of $16,977. As part of the purchase price allocation of the acquisition and merger, the Company recognized $8,700 of acquired licenses, $2,600 of trade names and trademarks and $6,335 of goodwill based on the consideration transferred and fair value of
net
assets acquired.
For further details on the acquisitions and purchase price allocations, see Note 7.
Year Ended December 31, 2021
In 2021, management assessed indicators of impairment and concluded the below for the respective RUs:
Retail, Production and Ancillary Cannabis Reporting Units
Management did not identify any significant negative triggering events that would suggest it is more likely than not that impairment exists. Therefore, further analysis was not required for these RUs.
 
10

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
Pure Ratios RU
As of June 30, 2022 and December 31, 2021, the accumulated impairment is $13,400, which is due to goodwill impairment of the entire outstanding balance of goodwill on the Pure Ratios segment for the year ended December 31, 2020. As a result, the segment does not have a balance of goodwill or intangible assets remaining as of December 31, 2021.
Note 7: ACQUISITIONS AND BUSINESS COMBINATIONS
NECC Merger Agreement
On January 28, 2022, the Company entered into the merger agreement (the “NECC Merger”) with NECC, Kenneth V. Stevens (“Mr. Stevens”), who is the sole owner of all of the issued and outstanding capital stock of NECC, and 4Front NECC Acquisition Co., a Massachusetts corporation (the “NECC Merger Sub”). At the effective time of the merger, the Company (i) paid Mr. Stevens cash in the amount of $9,000,000, and (ii) issued Mr. Stevens 28,571,428 Class A Subordinate Voting shares of the Company (the “SVS”).
In connection with the consummation of the NECC Merger on January 28, 2022, Mission Partners RE, LLC, a Delaware limited liability company wholly owned by the Company (“Mission Partners RE”), and Mr. Stevens entered into the first amendment to that certain membership interest purchase agreement (the “Everett Purchase Agreement”). Pursuant to the Everett Purchase Agreement, the Company (through Mission Partners RE) completed its acquisition of 100% of the issued and outstanding membership interests of 29 Everett Street LLC, a Massachusetts limited liability company (the “Everett LLC”), which was solely held by Mr. Stevens and which owns certain real property that is currently leased to and used by NECC. The Company (i) paid Mr. Stevens cash in the amount of $16,000,000, and (ii) issued Mr. Stevens a promissory note in the initial principal amount of $2,000,000, which will bear interest at an annual rate of ten percent (10%) and mature
d
on the
six-month
anniversary of January 28, 2022.
On July 28, 2022, the parties amended the promissory note to provide for payment of half the principal on the initial maturity date, and the remaining principal and all accrued interest on September 12, 2022. The Merger and Purchase Agreement were recorded as one transaction (collectively, referred to as the “NECC Acquisitions”), as the entities were commonly owned by the same individual and the purchase of Everett LLC was contingent on the Merger with NECC.
The NECC Merger was accounted for as a business combination in accordance with ASC 805. The Company has determined preliminary fair values of the assets acquired and liabilities assumed in the NECC Merger. These values are subject to change as the Company completes its determination of the fair value of assets acquired and liabilities assumed. Upon acquisition of NECC and Everett LLC on January 28, 2022, the Company consolidated the operations of Everett LLC into NECC. As of the date of acquisition, the Company recognized NECC under the THC Cannabis segment as part of segment reporting.
The Company entered into the NECC Merger in order to acquire cannabis licenses, as well as property and equipment held by NECC to increase the Company’s presence in Massachusetts and the northeastern United States. As part of the NECC, the Company incurred $130 in restructuring costs, which were included in transaction and restructuring related expenses and expensed as incurred. As part of the NECC Merger, the Company incurred $544 in transaction costs, which were included in transaction and restructuring related expenses and expensed as incurred.
 
11

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
The following tables present the preliminary purchase price allocation for the NECC Merger:
 
Cash consideration
   $ 25,000  
Seller note
     2,000  
Equity consideration - common stock
     18,200  
    
 
 
 
Total Purchase Price
   $ 45,200  
    
 
 
 
 
Description
  
Fair value
 
Assets acquired:
        
Cash
   $ 2  
Inventory
     213  
Property, plant, and equipment
     15,238  
Intangible asset - licenses
     18,000  
    
 
 
 
Total assets acquired
   $ 33,453  
    
 
 
 
Liabilities assumed:
        
Accounts payable
     800  
    
 
 
 
Total liabilities assumed
   $ 800  
    
 
 
 
Estimated fair value of net assets acquired
   $ 32,653  
    
 
 
 
Estimated Goodwill
   $ 12,547  
    
 
 
 
Goodwill and Intangible Assets
Goodwill is represented by the future potential for the generation of positive cash flows and future relationships associated with the Company’s operations. While NECC had yet to generate revenues as of the date of the Merger, the Company identified that the inputs of the business were in place to begin generating revenue during fiscal year 2022. The Company adjusts provisional goodwill balance when new information is obtained regarding the valuation of acquired assets and liabilities during a
one-year
measurement period from the date of acquisition in accordance with ASC
805-10.
The Company has determined that the goodwill recognized in the above acquisition is not deductible for tax purposes.
The intangible assets acquired by the Company consist of cannabis licenses for operations. Utilizing alike licenses as a benchmark, the Company determined that the licenses acquired are indefinite lived assets.
Island Merger Agreement
On March 30, 2022, the Company entered into an agreement and plan of merger (the “Island Merger Agreement”) by and among the Company, Island Merger Sub, Island, and Navy (together the “Island Parties”). Pursuant to the terms and conditions of the Merger Agreement, Island Merger Sub merged with and into Island, with Island surviving the merger and continuing its corporate existence as a wholly owned subsidiary of the Company (the “Island Merger”). The Island Merger Agreement was to be effective as of April 25, 2022 (the “Effective Date”).
 
12

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
On the Effective Date, the Island Parties consummated the Island Merger, pursuant to the terms and conditions of the Island Merger Agreement, as amended. However, due to administrative and technical issues at the California Office of the Secretary of State, the Island Parties did not receive the certificate of merger evidencing the closing of the Island Merger as of the Effective Date until April 25, 2022. At the Effective Date, pursuant to the terms and conditions of the Island Merger Agreement, as amended, the Company issued to certain shareholders and debtholders of Island an aggregate of: (i) 8,783,716 Class A Subordinated Voting Shares of the Company (the “SVS”); (ii) 6%
54-month,
subordinated promissory notes (the “Island Merger Notes”) in the aggregate principal amount of $6,500,000; and (iii) warrants to purchase 2,999,975 SVS at a price of $1.00 per SVS (the “Warrants”, and together with the SVS and Island Merger Notes, the “Island Merger Consideration”).
On April 22, 2022, the Parties entered into the first amendment to the Island Merger Agreement to replace the requirement that certain noteholders fund a letter of credit to Island of up to $1,000,000. In lieu of funding a
letter
 of credit, the noteholders agreed to pay the full $1,000,000 in cash to Island on or prior to the closing of the transactions contemplated by the Island Merger Agreement.
The Island Merger was accounted for as a business combination in accordance with ASC 805. The Company has determined preliminary fair values of the assets acquired and liabilities assumed in the Island Merger. These values are subject to change as the Company completes its determination of the fair value of assets acquired and liabilities assumed. Upon acquisition of Island and Navy on April 25, 2022, the Company consolidated the operations of Navy into Island. As of the date of acquisition, the Company recognized Island under the THC Cannabis segment as part of segment reporting.
The Company entered into the Island Merger in order to add new high-quality products to the Company’s growing brand portfolio, including diverse lines of
pre-rolls,
flower and infused products, as well as reduce production costs. As part of the Island Merger, the Company incurred
$
1,288 in restructuring costs, which were included in transaction and restructuring related expenses and expensed as incurred. As part of the Island Merger, the Company incurred $47 in transaction costs, which were included in transaction and restructuring related expenses and expensed as incurred.
The following tables present the preliminary purchase price allocation for the Island Merger:
 
Seller note
   $ 10,000  
Equity consideration - common stock
     6,245  
Equity consideration - warrants
     732  
    
 
 
 
Total Purchase Price
   $ 16,977  
 
Description
  
Fair value
 
Assets acquired:
        
Cash
   $ 458  
Accounts receivable
     876  
Inventory
     3,072  
Prepaid expenses and other current assets
     424  
Property and equipment, net
     2,214  
Operating lease - right of use asset
     10,227  
Intangible assets
     11,300  
    
 
 
 
Total assets acquired
   $ 28,571  
    
 
 
 
Liabilities assumed:
        
Accounts payable
   $ 1,356  
Accrued expenses and other liabilities
     2,566  
Contract liabilities
     3,535  
Lease liabilities
     10,227  
Notes payable
     245  
Total liabilities assumed
  
$
17,929  
    
 
 
 
Estimated fair value of net assets acquired
   $ 10,642  
    
 
 
 
Estimated Goodwill
   $ 6,335  
    
 
 
 
 
13

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
Goodwill and Intangible Assets
Goodwill is represented by the future potential for the generation of positive cash flows and future relationships associated with the Company’s operations. The Company adjusts provisional goodwill balance when new information is obtained regarding the valuation of acquired assets and liabilities during a
one-year
measurement period from the date of acquisition in accordance with ASC
805-10.
The Company has determined that the goodwill recognized in the above acquisition is not deductible for tax purposes.
The intangible assets acquired by the Company consist of cannabis licenses
,
trade names and trademarks for operations. Utilizing alike licenses as a benchmark, the Company determined that the licenses acquired are indefinite lived assets and the trade names and trademarks have a life of ten years.
Unaudited Pro Forma Results
The following unaudited pro forma financial information presents the results of operations of the Company, NECC, and Island for the six months ended June 30, 2022 and 2021, as if the acquisitions had occurred as of the beginning of the first period presented instead of on January 28 and April 25, 2022, respectively. The pro forma information does not necessarily reflect the results of operations that would have occurred had the entities been a single company during those periods.
The unaudited pro forma financial information for the Company including NECC and Island for the three months ended June 30, 2022 is as follows:
 
 
  
For the For the Three Months Ended June 30,
 
 
  
2022
 
  
2021
 
 
  
Reported
 
  
Proforma
 
  
Reported
 
  
Proforma
 
Revenues
   $ 28,439      $ 28,706      $ 27,121      $ 28,922  
(Loss) income from operations
     (4,099      (5,444      668        (936 )
    
 
 
    
 
 
    
 
 
    
 
 
 
Net loss
   $ (6,546    $ (8,932    $ (6,218    $ (8,115
    
 
 
    
 
 
    
 
 
    
 
 
 
Basic and diluted earning (loss) per share
   $ (0.01    $ (0.01    $ (0.01    $ (0.01
The unaudited pro forma financial information for the Company including NECC and Island for the six months ended June 30, 2022 is as follows:
 
 
  
For the For the Six Months Ended June 30,
 
 
  
2022
 
  
2021
 
 
  
Reported
 
  
Proforma
 
  
Reported
 
  
Proforma
 
Revenues
   $ 54,487      $ 56,113      $ 50,091      $ 53,286  
(Loss) income from operations
     (5,340      (9,399      1,021        (2,490
    
 
 
    
 
 
    
 
 
    
 
 
 
Net loss
   $ (12,440    $ (20,817    $ (17,302    $ (20,813
    
 
 
    
 
 
    
 
 
    
 
 
 
Basic and diluted earning (loss) per share
   $ (0.02    $ (0.03    $ (0.02    $ (0.04
Note 8: LEASES
The Company has operating leases for its facilities where the Company conducts its operations. These leases have remaining lease terms ranging from 1 year to 19.2 years.
All real estate leases are recorded on the balance sheet. Equipment and other
non-real
estate leases with an initial term of twelve months or less are not recorded on the balance sheet. Lease agreements for some locations provide for rent escalations and renewal options. Many leases include one or more options to renew the lease at the end of the initial term. The Company considered renewals in its
right-of-use
assets and operating lease liabilities. Certain real estate leases require payment for taxes, insurance and maintenance which are considered
non-lease
components. The Company accounts for real estate leases and the related fixed
non-lease
components together as a single component.
The Company determines if an arrangement is a lease at inception. The Company must consider whether the contract conveys the right to control the use of an identified asset. Certain arrangements require significant judgment to determine if an asset is specified in the contract and if the Company directs how and for what purpose the asset is used during the term of the contract.
There are no material residual guarantees associated with any of the Company’s leases, and there are no significant restrictions or covenants included in the Company’s lease agreements. Certain leases include variable payments related to common area maintenance and property taxes, which are billed by the landlord, as is customary with these types of charges for office space.
 
14

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
The Company’s lease agreements occasionally provide an implicit borrowing rate. When implicit borrowing rates are provided, the Company utilizes these implicit borrowing rates to calculate
right-of-use
assets and liabilities at the end of each reporting period. The Company may enter into leases that do not provide an implicit borrowing rate. When an implicit borrowing rate is not provided, the Company uses a benchmark approach to derive an appropriate imputed discount rate. The Company will benchmark itself against other companies of similar credit ratings and compare quality and derive an imputed rate, which was used in a portfolio approach to discount its lease liabilities.
For the three months ended June 30, 2022 and 2021 the Company recorded $2,595 and $2,400 in operating lease expense, respectively. For the six months ended six months ended June 30, 2022 and 2021 the Company recorded $7,417 and $4,868 in operating lease expense, respectively.
(a) The Company as a Lessee
The following table summarizes the Company’s operating leases:
 
    
Classification - Consolidated Balance Sheet
  
June 30, 2022
    
December 31, 2021
 
Assets
                      
Operating lease assets
  
Operating Lease Assets
   $ 106,406      $ 100,519  
Liabilities
                      
Current
                      
Operating
  
Current portion of operating lease liabilities
     4,121        3,629  
Noncurrent
                      
Operating
  
Operating lease liabilities
     101,380        93,111  
         
 
 
    
 
 
 
Total lease liabilities
        $ 105,501      $ 96,740  
         
 
 
    
 
 
 
The components of lease expense are included in cost of goods sold, general and administrative expenses, and selling and marketing expenses, based on the underlying use of the
right-of-use
asset.
Maturities of lease liabilities for third-party operating leases as of June 30, 2022 were as follows:
 
    
Operating Leases
 
2022
   $ 8,329  
2023
     16,987  
2024
     17,491  
2025
     17,633  
2026
     18,056  
2027
     18,076  
2028 and Thereafter
     234,359  
    
 
 
 
Total undiscounted cash flows
   $ 330,931  
Less discounting
     (225,430
    
 
 
 
Total lease payments
   $ 105,501  
    
 
 
 
The Company has
right-of-use
assets and lease liabilities for leased real estate for dispensaries, cultivation and production facilities and office space. The incremental borrowing rate used for leases for 2022 was 10.25 - 18% and was 10.25 - 17% for 2021.
 
15

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
(b) The Company as a Lessor:
The Company leases a building in Elma, Washington that is subleased by the Company to a third party. This sublease is classified as a finance lease with a long term lease receivable balance of $6,541 and a short term lease receivable balance of $3,405 as of June 30, 2022 compared to a long term lease receivable balance of $6,748 and a short term lease receivable balance of $3,630 as of December 31, 2021. This lease generated $676 of the $2,951 and $570 of the $2,669 in real estate income for the three months ended June 30, 2022 and 2021, respectively. This lease generated $1,368 of the $5,916 and $1,361 of the $5,559 in real estate income for the six months ended June 30, 2022 and 2021, respectively.
The Company owned buildings in Olympia, Washington that were leased to a third party. This lease was classified as a finance lease. On December 17, 2020, the Company sold the Olympia building and other assets as part of a sale and leaseback transaction and this lease was cancelled. The Company applied ASC 842 to a new sublease to the same third party and classified the new sublease as an operating lease. The lease receivable was sold to the purchaser of the assets as part of the sale and leaseback transaction. This lease generated $2,275 of the $2,951 and $2,099 of the $2,669 in real estate income for the three months ended June 30, 2022 and 2021, respectively. This lease generated $4,548 of the $5,916 and $4,198 of the $5,559 in real estate income for the six months ended June 30, 2022 and 2021, respectively.
The following table summarizes changes in the Company’s lease receivables:
 
    
June 30, 2022
    
December 31, 2021
 
Balance, beginning of the year
   $ 10,378      $ 11,045  
Interest
     1,368        2,783  
Lease payments received
     (1,800      (3,450
    
 
 
    
 
 
 
Balance, end of the period
  
$
9,946      $ 10,378  
Less current portion
     (3,405      (3,630
    
 
 
    
 
 
 
Long-term lease receivables
   $ 6,541      $ 6,748  
    
 
 
    
 
 
 
Future minimum lease payments receivable (principal and interest) on the leases are as follows:
 
    
Operating Leases
 
2022
   $ 1,830  
2023
     1,575  
2024
     —    
2025
     —    
2026
     —    
Thereafter
     —    
    
 
 
 
Total minimum lease payments
     3,405  
Effect of discounting
     (431
Present value of minimum lease payments
     2,974  
Present value of residual value of leased property
     6,972  
    
 
 
 
Total lease receivable
     9,946  
Current portion lease receivable
     (3,405
    
 
 
 
Long-term lease receivable
   $ 6,541  
    
 
 
 
 
16

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
Note 9: NOTES PAYABLE AND CONVERTIBLE NOTES
The Company’s notes payable and convertible notes are as follows:
 
    
LI Lending,
LLC
   
May 2020
Convertible
Notes
   
2022 Island
Global
Holdings
Related Party
Notes
    
May 2020
Convertible
Notes (Swap)
   
October 2021
Convertible
Note
    
Other
Loans
   
Total
 
Balance, December 31, 2020
   $ 45,362     $ 2,855     $         $ 11,867     $ —        $ 6,931     $ 67,015  
    
 
 
   
 
 
   
 
 
    
 
 
   
 
 
    
 
 
   
 
 
 
Loans advanced, net
              —                            14,376        930       15,306  
Loan payments
     (4,671              —          —                   (1,079     (5,750
Converted to equity
     —         (5,852               (11,867     —                   (17,719
Accrued interest
     7,575       2,997                          265        1,124       11,961  
    
 
 
   
 
 
   
 
 
    
 
 
   
 
 
    
 
 
   
 
 
 
Balance, December 31, 2021
   $ 48,266     $        $         $        $ 14,641      $ 7,906     $ 70,813  
    
 
 
   
 
 
   
 
 
    
 
 
   
 
 
    
 
 
   
 
 
 
Loans advanced, net
     —         —         245        —                   13,138       13,383  
Loan payments
     (2,526              —          —                   (130     (2,656
Converted to equity
     —         —                                      (2,784     (2,784
Accrued interest
     3,381                                   564        233       4,178  
    
 
 
   
 
 
   
 
 
    
 
 
   
 
 
    
 
 
   
 
 
 
Balance, June 30, 2022
   $ 49,121     $        $ 245      $        $ 15,205      $ 18,363     $ 82,934  
Less current portion
     —         —         —          —                   (8,235     (8,235
    
 
 
   
 
 
   
 
 
    
 
 
   
 
 
    
 
 
   
 
 
 
Long-term portion
   $ 49,121     $        $ 245      $        $ 15,205      $ 10,128     $ 74,699  
    
 
 
   
 
 
   
 
 
    
 
 
   
 
 
    
 
 
   
 
 
 
Convertible Notes
On May 14, 2020, the Company issued $5,827 in convertible notes to existing investors in the Company. The notes pay interest of 5% per annum and have a maturity date of February 28, 2022. The notes can be converted into SVS of the Company for $0.25 per share at any time at the option of the holder.
The Company was permitted to require
 mandatory conversion at any time that the Company’s stock price remains above $0.50 for 45 consecutive days. In 2021, the Company enacted the mandatory conversion feature and converted the May 2020 Convertible Note balance to subordinate voting shares.
As part of issuing the convertible notes, the investors were given the right to exchange stock in the Company into separate convertible notes (swap notes). In total 29,448,468 shares with a value of $13,661 were exchanged for $13,661 in convertible notes. These notes were effective May 28, 2020, have a maturity date of May 28, 2025, and can be converted into Class A Subordinate Voting Shares of the Company for $0.46 per share at any time at the option of the holder. The notes pay no interest if the Company’s annual revenue is greater than $15,000, and 3% annually otherwise. The Company can require mandatory conversion at any time that the Company’s stock price remains above $0.92 for 45 consecutive days. In 2021, the Company exercised the mandatory conversion feature and converted the May 2020 Convertible Note (Swap) balance to subordinate voting shares.
On October 6, 2021, the Company entered into a convertible promissory note purchase agreement for $15,000, less issuance costs of $624, resulting in net proceeds of $14,376. The notes pay interest of 6% per annum and have a maturity date of October 6, 2024. The notes can be converted into SVS of the Company for $1.03 per share at any time at the option of the holder. As of June 30, 2022, no payments have been made for this loan.
LI Lending LLC
On May 10, 2019, the Company entered into a loan agreement with LI Lending LLC, a related party, for $50,000. LI Lending LLC is related because an officer of the Company is a part-owner of LI Lending LLC. As of June 30, 2022, the Company had drawn $45,000 on the loan in two amounts, an initial $35,000 and a final $10,000, both bearing a 10.25% and 12.25% interest rate, respectively. The outstanding balance as of June 30, 2022 is $49,457, less debt discount of $336, for a net balance of $49,121. See Note 13 for further discussion of this related party transaction.
In April 2020, the loan was amended. In exchange for consent to allow the sale of the Pennsylvania and Maryland assets and the release of related collateral, the Company agreed to make prepayments of principal to LI Lending LLC in the amount of $250 per month for an eight-month period beginning on May 1, 2020. The $2,000 prepayment was applied to the initial $35,000 amount, decreasing the balance to $33,000. Additionally, the Company agreed to pay an increased interest rate of 12.25% on the final $10,000 of the loan until such time as this amount has been paid down, with the initial $33,000 amount continuing to be subject to the original 10.25% interest rate.
In December 2020, the loan was amended to allow for the release of collateral for the sale and leaseback transactions described in Note 8 above, which was entered into with Innovative Industrial Properties, Inc. (“IIPR”). The amendment increased both interest rates by 2.5% on the loan amounts but allowed the payments resulting from the incremental interest to be deferred until January 1, 2022. The Company elected to defer payment, and the additional 2.5% interest is accrued each month and added to the balance of the loan. The Company was required to make interest-only payments monthly of 10.25% on the initial $33,000 and 12.25% on the final $10,000 of the loan until January 1, 2022 when the interest rates of 12.75% for the initial $33,000 and 14.75% for the final $10,000 took effect for the remaining term.
The loan matures on May 10, 2024. An exit fee of 20% of the principal balance will be due as principal is repaid. Accrued interest expense of $3,381 includes a loan discount accretion expense of $165 for the six months ended June 30, 2022. Accrued interest expense of $1,490 includes a loan discount accretion expense of $40 for the three months ended June 30, 2022. On January 1, 2022, the Company began making the required principal payments in addition to the interest payments for this loan. As of June 30, 2022, the Company has made $2,526 in payments on this loan.
 
17

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
Other
Outstanding as of June 30, 2022 were other payables totaling $18,363 which include notes issued as part of the acquisitions of Healthy Pharms, NECC, and Arkansas entities as follows:
 
Other
              
 
Subsidiary
  
Terms
  
June 30, 2022
    
December 31, 2021
 
Healthy Pharms Inc.   
Unsecured convertible note, due
November 18
, 2021
at 12% per annum
   $         $ 2,784  
Healthy Pharms Inc.   
Unsecured promissory note at $0.50 per share due December 18, 2022 at 10% per annum (1)
     3,377        3,213  
Island Global   
Promissory note due October 25, 2026 at 6% per annum
     10,128            
NECC   
Promissory note due September 12, 2022 at 10% per annum
     2,084            
Om of Medicine, LLC   
Promissory note due September 1, 2022 at 12% per annum (3)
     981            
Arkansas Entities   
Unsecured Promissory note due December 1, 2022, monthly interest payments at 14% per annum
     1,709        1,709  
Equipment Loans   
Secured by equipment, monthly payments beginning in 2021 at 15% per annum
     63        49  
Other   
Various
     21        151  
         
 
 
    
 
 
 
Total Notes Payable and Convertible
Notes
        $ 18,363      $ 7,906  
         
 
 
    
 
 
 
 
(1)
In November 2021, the unsecured promissory note was modified to be due and payable in full on or before December 18, 2022. The Company concluded the extension resulted in a debt modification under
ASC 470
.
(2)
In July 2022, the promissory note was modified, whereby 50% of the outstanding note payable was paid on July 28, 2022, and the remaining outstanding balance of the note was to be payable in full on or before September 12, 2022.
(3)
In April 2022, the Company entered into a seller note payable to pay the outstanding balance due resulting from the 2021 Om earnout in connection with prior period contingent considerations. The note bore 10% interest per annum and was due to be paid in full by July 1, 2022. At the time of the issuance of the note, the liability was current and was certain to be paid during 2022. In July 2022, the Company amended the note, whereby the Company paid $345 of the remaining balance on the seller note and the term of the remaining balance of the seller note was extended to September 1, 2022, bearing interest at 12% per annum. If payment is not received in full by September 1, 2022, the remaining balance on the note will accrue interest at
20% per
annum until payment is made in full. See Note 14 for further details on contingent considerations and the Om earnout.
Future minimum payments on the notes payable and convertible debt are as follows:
 
    
June 30, 2022
 
2022
   $ 8,235  
2023
         
2024
     64,326  
2025
         
2026
     12,874  
Thereafter
         
    
 
 
 
Total minimum payments
     85,435  
Effect of discounting
     (2,501
    
 
 
 
Present value of minimum payments
     82,934  
Less current portion
     (8,235
    
 
 
 
Long-term portion
   $ 74,699  
    
 
 
 
Construction Finance Liability
On January 28, 2022, a wholly owned subsidiary of the Company acquired property at 29 Everett in conjunction with the NECC Merger (see Note 7 for further details on the transaction). Concurrently, effective January 28, 2022, the Company sold a portion of the property it had acquired in the acquisition for
 
$16,000
.
In connection with the sale of the property at 29 Everett, the Company agreed to lease the location back for cultivation, effective on January 28, 2022. The details of the lease included three purchase options that the Company can exercise, in which the Company has the ability to repurchase the property on either the second, fourth, or sixth anniversary of the lease agreement. The Company determined that the purchase and subsequent leasing of the land, building, and equipment at NECC was a sale of real estate, as the property and equipment sold as part of the building were interrelated with the building. Under
ASC 842 - Leases
, lease arrangements where assets are sold and leased back, whereby the transaction fails to meet the definition of a sale of an asset, does not meet the definition of a sale because control is never transferred to the buyer-lessor. The transaction did not meet the sale-and-lease back criteria under ASC 842, and the transaction was treated as a failed sale-leaseback financing arrangement. On January 28, 2022, the Company recorded a construction finance liability for the proceeds received from the sale to recognize a liability resulting from the failed sale-leaseback transaction.
The initial term of the agreement is 20 years, with two options to extend the term for five years each. The initial monthly rent payment is equal to $140 for the first year of the agreement, with 3% annual increases over the life of the agreement. As of June 30, 2022, the total finance liability associated with this transaction is $16,000
. The total interest expense incurred during the six months ended June 30, 2022 was $700.
 
18

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
Note 10: SHARE CAPITAL AND EQUITY
The Company has authorized an unlimited number of Class A Subordinate Voting Shares (“SVS”) and Class C Multiple Voting Shares (“MVS”), all with no par value. In December 2020, the shareholders of the Company passed a resolution to permit the Company to convert all Class B Subordinate Voting Shares (“PVS”) shares into Class A shares and cancel the Class B PVS equity class, which occurred in 2020.
All share classes are included within share capital in the consolidated statements of stockholders’ equity on an
as-
converted basis. Each share class is entitled to notice of and to attend at any meeting of the shareholders, except a meeting of which only holders of another particular class of shares will have the right to vote. All share classes are entitled to receive dividends, as and when declared by the Company, on an
as-converted
basis, and no dividends will be declared by the Company on any individual class unless the Company simultaneously declares or pays dividends on all share classes. No subdivision or consolidation of any share class shall be made without simultaneously subdividing or consolidating all share classes in the same manner.
Voting shares activity for the periods presented is summarized as follows:
 
    
Class A Subordinate
Voting Shares
    
Class C Multiple
Voting Shares
    
Total
 
Balance, December 31, 2020
     537,575,044        1,276,208        538,851,252  
    
 
 
    
 
 
    
 
 
 
Share capital issuances
     55,330,352                  55,330,352  
    
 
 
    
 
 
    
 
 
 
Balance, December 31, 2021
     592,905,396        1,276,208        594,181,604  
    
 
 
    
 
 
    
 
 
 
Share capital issuances
     43,731,290                  43,731,290  
    
 
 
    
 
 
    
 
 
 
Balance, June 30, 2022
     636,636,686        1,276,208        637,912,894  
    
 
 
    
 
 
    
 
 
 
Class A Subordinate Voting Shares
Holders of Class A Subordinate Voting Shares are entitled to one vote in respect of each SVS.
Class C Multiple Voting Shares
Holders of Class C Multiple Voting Shares are entitled to 800 votes in respect of each MVS. One MVS can convert to one SVS but are not convertible until the later of the date that (i) the aggregate number of PVS and MVS held by the Initial Holders (being the MVS holders on their initial issuance) are reduced to a number which is less than 50% of the aggregate number of PVS and MVS held by the Initial Holders on the date of completion of the Business Combination with Cannex, and (ii) 3 years following the date of the business combination with Cannex.
 
Series
  
Shares outstanding as of
June 30, 2022
    
As converted to SVS
Shares
 
Class A - Subordinate Voting Shares
     636,636,686        636,636,686  
Class C - Multiple Voting Shares
     1,276,208        1,276,208  
    
 
 
    
 
 
 
       637,912,894        637,912,894  
    
 
 
    
 
 
 
On November 23, 2020, the Company closed a brokered private placement and issued 24,644,500 Units at a price of C$0.70 per Unit. Each Unit is comprised of one subordinate voting share of the Company and
one-half
of a subordinate voting share purchase warrant. Each whole warrant entitles the holder to purchase one subordinate voting share for a period of two years from the date of issuance at an exercise price of C$0.90 per subordinate voting share. Net proceeds from this transaction were $11,557 net of share issuance costs of $690.
 
19

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
Because of the Canadian dollar denominated exercise price, these warrants do not qualify to be classified within equity and are therefore classified as derivative liabilities at fair value with changes being reported through the statement of operations. On November 23, 2020, the warrants were valued using the Black Scholes option pricing model at $4,229 using the following assumptions: Share Price: C$0.94; Exercise Price: C$0.90; Expected Life: 2 years; Annualized Volatility: 87.73%; Dividend yield: 0.00%; Discount Rate: 0.16%; C$ Exchange Rate:1.31.
On June 30, 2022, the warrants were revalued using the Black Scholes option pricing model, using the following assumptions: Share Price: C$0.71; Expected Life: 0.4 years; Annualized Volatility: 61.40%; Dividend yield: 0.00%; Discount Rate: 2.51%; C$ Exchange Rate: 1.29. The decrease in the value of the derivative liability of $3,074 is reflected in the statement of operations as a $3,074 gain on the change in fair value of the derivative liability.
Note 11: WARRANTS
As of June 30, 2022, there were share purchase warrants outstanding to purchase up to 29,103,553 SVS shares:
 
Series
  
Number of warrants
    
Weight-average

exercise price
 
Balance, December 31, 2021
     26,192,237      $ 0.75  
Issued
     2,999,975        1.00  
Exercised
     (88,659      0.56  
    
 
 
    
 
 
 
Balance, June 30, 2022
     29,103,553      $ 0.75  
    
 
 
    
 
 
 
As of June 30, 2022, the Company has the following warrants outstanding:
 
Warrants Outstanding
  
Exercise Price
    
Expiry Date
 
10,403,150
   C$  0.90      November 23, 2022  
209,426
   C$  0.70      November 23, 2022  
12,135,922
   $ 0.82      December 17, 2022  
2,230,080
   $ 0.67      January 29, 2023  
2,999,975
   $ 1.00        April 13, 2024  
625,000
   C$  0.80      October 6, 2024  
500,000
   C$  0.80      October 6, 2025  
 
                 
29,103,553
                 
 
                 
 
*
Represents warrants that are exercisable as of June 30, 2022.
 
20

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
Note 12: SHARE-BASED COMPENSATION
The Company adopted two equity incentive plans where the Company may grant Class A stock options. Under the terms of the plans, the maximum number of stock options which may be granted are a total of 10% of the number of shares outstanding assuming conversion of all shares to SVS. The exercise price for stock options issued under the plans will be set by the compensation committee of the board of directors but will not be less than 100% of the fair market value of the Company’s shares on the grant date. Stock options have a maximum term of 10 years from the date of grant. Stock options vest at the discretion of the Board.
As of June 30, 2022, the Company had the following options outstanding and exercisable on an
as-converted
basis:
 
Grant Date
  
Strike Price in
CAD$
    
Outstanding
Options
    
Exercisable
Options
    
Life Remaining
(years)
 
July 31, 2019
     0.10        6,245,840        6,245,840        2.22  
July 31, 2019
     1.00        7,783,332        7,783,332        0.45  
July 31, 2019
     1.00        1,166,667        1,166,667        1.27  
July 31, 2019
     1.50        508,333        508,333        1.95  
July 31, 2019
     1.50        800,000        800,000        1.96  
August 22, 2019
     0.80        5,237,720        4,459,942        2.15  
August 22, 2019
     1.00        6,150,000        5,522,222        2.15  
November 1, 2019
     0.80        1,200,000        1,000,000        2.34  
February 3, 2020
     0.80        348,333        148,333        2.60  
June 8, 2020
     0.80        25,000        12,500        2.94  
July 31, 2020
     0.80        1,200,000        1,150,000        3.09  
September 15, 2020
     0.86        7,315,860        7,315,860        3.21  
October 2, 2020
     0.77        3,000,000        3,000,000        3.26  
November 24, 2020
     0.94        1,675,000        1,675,000        3.41  
December 2, 2020
     1.11        2,900,000        2,900,000        3.43  
December 21, 2020
     1.06        1,200,000        600,000        3.48  
March 18, 2021
     1.63        6,375,000        4,158,333        3.72  
April 2, 2021
     1.36        166,667        100,000        3.76  
April 21, 2021
     1.58        175,000        116,667        3.81  
June 23, 2021
     1.56        250,000        216,667        3.98  
November 11, 2021
     1.33        25,000        6,250        4.37  
January 25, 2022
     0.89        975,000        209,896        4.58  
February 1, 2022
     0.84        100,000        20,556        4.59  
February 17, 2022
     0.85        100,000        14,167        4.64  
March 1, 2022
     1.09        200,000        33,333        4.67  
April 27, 2022
     0.90        1,200,000        71,111        4.83  
June 17, 2022
     0.77        3,735,000        723,661        4.97  
             
 
 
    
 
 
    
 
 
 
                60,057,752        49,958,670        2.72  
Stock option activity is summarized as follows:
 
    
Number of
Options
    
Weighted
Average Price
CAD$
    
Weighted
Average Years
 
Balance December 31, 2020
     50,427,065        0.84        3.72  
Granted
     7,900,000        1.62        5.00  
Exercised
     (2,737,326      1.04        —    
Forfeited/ Expired
     (1,306,987      0.43        —    
    
 
 
    
 
 
    
 
 
 
Balance December 31, 2021
     54,282,752        0.94        2.97  
Granted
     6,435,000        0.83        5.00  
Exercised
     (51,975      0.80        —    
Forfeited/ Expired
     (608,025      1.62        —    
    
 
 
    
 
 
    
 
 
 
Balance June 30, 2022
     60,057,752        0.92        2.72  
 
21

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
During the six months ended June 30, 2022 and 2021, the Company recognized share-based compensation of $1,428 and $5,375. During the three months ended June 30, 2022 and 2021, the Company recognized share-based compensation of $390
 
and $2,979, respectively.
In determining the amount of equity-based compensation during the year, the Company used the Black-Scholes option pricing model to establish fair value of options granted during the year with the following key assumptions:
 
    
2022
   
2021
 
Risk-Free Interest Rate
     2.42     0.87 % to 0.92
Expected Life (years)
     5.00       5.00  
Expected Annualized Volatility
     71.30     86.2 % to 93.53
Forfeiture rate
              
Expected Dividend Yield
              
Note 13: RELATED PARTIES
Related party transactions
LI Lending LLC
Linchpin Investors LLC (“Linchpin”), a subsidiary of the Company, and LI Lending LLC (“LI Lending”) entered into a Construction Loan Agreement dated May 10, 2019, as amended, whereby Linchpin received an
up-to
$45,000 loan from LI Lending of which $48,300 was outstanding as of December 31, 2021. Mr. Gontmakher, the CEO of the Company, and Roman Tkachenko, a director of the Company, each hold a 14.28% ownership interest in LI Lending. The loan matures in May 2024 and bears interest at 10.25%, payable monthly in cash. Upon maturity, an exit fee of $9 million is payable, for a total payable at maturity of $54 million. $49,457 of the loan advanced includes the notes payable and accrued interest less debt discount of $336 that was outstanding as of June 30, 2022. Of the $49,121 outstanding at June 30, 2022, $3,381 represents interest accrued through June 30, 2022. See Note 9 for details on the outstanding note payable.
Pure Ratios
Leonid Gontmakher, Chief Executive Officer of the Company, holds an interest in an entity related to iWolf Management, LLC, an online marketing company serving the online CBD market which provided online marketing services during 2020 and 2019 for the Company’s Pure Ratios division. Pure Ratios paid $313 for the three and six months ended June 30, 2021 to this vendor for management fees, pass through marketing costs and customer service. Pure Ratios did not make any such payments during the six months ended June 30, 2022.
MP Illinois
The Company maintains a contractual relationship with entities that are wholly owned by MP Illinois, a single-member LLC owned by Mr. Joshua N. Rosen, a former officer and director of the Company. The Company holds a nominee agreement whereby the Company receives a 100%
beneficial (but not legal) interest IL Grown Medicine, LLC, the holder of a cultivation license in Illinois.
 
22

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 

Note 14: CONTINGENCIES
(a) Cannabis Industry
Cannabis is still considered a Schedule
I
 substance under the Controlled Substance Act. As such, there is an inherent risk related to the federal government’s position on cannabis; additionally, the risk exists, due to the Company’s business in cannabis, that third party service providers could suspend or withdraw services and as well as the risk that regulatory bodies could impose certain restrictions on the issuer’s ability to operate in the U.S.; however, the Company has deemed it not reasonable to estimate a potential liability related to the possible enforcement of laws against the medical cannabis industry.
(b) Contingent consideration payable
As part of the acquisition of Om of Medicine, LLC and Cannex’s prior acquisition of Pure Ratios, the Company is subject to contingent consideration payable to the sellers. The fair value of the contingent consideration, which is based on specific revenue levels achieved over a
2-3-year
period, is as follows:
 
    
Om of
Medicine
 
Balance, December 31, 2021
   $ 2,393  
Changes in fair value
     (2,393
    
 
 
 
Balance, June 30, 2022
         
Less: current portion
     —    
    
 
 
 
Long-term portion
   $     
The contingent consideration payable is measured at fair value based on unobservable inputs and is considered a Level 3 financial instrument. The determination of the fair value of these liabilities is primarily driven by the Company’s expectations of the respective subsidiaries achieving certain milestones. The expected milestones were assigned probabilities and the expected related cash flows were discounted to derive the fair value of the contingent consideration. The Company reached expected milestones during the year ended December 31, 2021, which resulted in a contingent consideration payment of $
1,373
that was due to be paid by the Company in 2022. The Company paid
 
$
412
of the outstanding balance in April 2022. As discussed in Note 9, in April 2022, the Company entered into a seller note to pay the outstanding balance of the liability. The term of the note expires in six months and accrues interest at 10% per annum. See Note 9 for the outstanding balance of the note payable as of June 30, 2022.
The Company had an outstanding balance of contingent consideration of $2,393
for the period ended December 31, 202
1
, which included the liability noted above. However, the Company performed analyses and determined that it does not anticipate the subsidiaries to reach the required milestones, as detailed below, for the year ended December 31, 2022. As a result, the Company estimated the contingent consideration to be $nil as of June 30, 2022.
OM of Medicine:
The contingent consideration payable is determined as the amount in excess of gross sales o
f $3,400 (for fiscal 2021) and $3,500 (2022) to a maximum payable of $6,900.
 
23

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
(c) Legal Matters
From time to time, the Company may be involved in certain disputes arising in the ordinary course of business. Such disputes, taken in the aggregate, are not expected to have a material adverse effect on the Company. There are also no proceedings in which any of the Company’s directors, officers, or affiliates is an adverse party or has a material interest adverse to the Company’s interest.
On May 15, 2017, the Company’s wholly-owned subsidiary, 4Front Advisors, LLC, entered into an Application, Training, and Consulting Agreement with 5Seat Investment, LLC and Kanna. A dispute arose about amounts owed to the subsidiary under the agreement, and on May 17, 2022, the parties agreed to settle the matter for payment of $600 to the Company’s subsidiary.
On January 26, 2022, Savills
,
Inc. sued the Company in the U.S. District Court for the Southern District of New York. That lawsuit alleged that the Company had breached an alleged agreement with Savills under which the Company was allegedly required to pay Savills a percentage of savings realized under certain incentive programs offered in some jurisdictions, which Savills would assist the Company in obtaining. Savills claimed damages of approximately
 
$
19,000
in connection with its claim that it obtained benefits for the Company allegedly valued at over
$
129,000
.
The Company denied these allegations, denied the Company had obtained such benefits, disputed Savills’ characterization of the facts, and denied liability. The Company filed a counterclaim against Savills alleging breach of contract by Savills. On August 3, 2022, the parties reached a confidential settlement in principle and agreed to dismissal of all claims. In accordance with the order of dismissal, if no application to restore the litigation is submitted by September 6, 2022, the case will be dismissed without prejudice.
Note 15: FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT
ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. The Company follows this authoritative guidance for fair value measurements, which defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles in the United States of America, and expands disclosures about fair value measurements. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:
 
Level 1
    
Quoted prices (unadjusted) in active markets for identical assets or liabilities;
 
Level 2
    
Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
 
Level 3
    
Inputs for the asset or liability that are not based on observable market data (unobservable inputs).
 
24

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the periods ended June 30, 2022 and December 31, 2021. The fair value of the Company’s cash, accounts receivable, other receivables, accounts payable and accrued expenses approximates carrying value due to their short-term nature. The Company’s notes receivable, lease receivables, contingent consideration payable, derivative liabilities, convertible notes payable, construction finance liability and notes payable approximate fair value due to the instruments bearing market rates of interest or their short term nature. As the interest rates utilized to calculate these instruments approximates market value interest rates, the carrying amounts of the instruments approximate fair value, which are primarily based on Level 1 inputs. The fair value of stock options granted were estimated based on a Black-Scholes model during the periods ended June 30, 2022 and December 31, 2021. The estimated fair value of the derivative liabilities, which represent embedded put included in the convertible notes payable, represent Level 3 measurements.
The following table details the fair value measurements within the fair value hierarchy of the Company’s financial instruments, which includes the Level 3 liabilities:
 
    
Fair value at June 30, 2022
 
    
Total
    
Level 1
    
Level 2
    
Level 3
 
Liabilities:
                                   
Derivative liability
   $ 428      $         $         $ 428  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total liabilities
   $ 428      $         $         $ 428  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
    
Fair value at December 31, 2021
 
    
Total
    
Level 1
    
Level 2
    
Level 3
 
Liabilities:
                                   
Derivative liability
   $ 3,502      $      $      $ 3,502  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total liabilities
   $ 3,502      $      $      $ 3,502  
    
 
 
    
 
 
    
 
 
    
 
 
 
The table below provides a summary of the changes in fair value of the derivative liabilities measured on a recurring basis using significant unobservable inputs (Level 3):
 
    
For the Six Months Ended June 30,
 
    
2022
    
2021
 
Derivative liability:
                 
Balance, beginning of period
   $ 3,502      $ 5,807  
(Gain) loss on fair value of derivative liability
     (3,074      2,843  
Change in fair value of derivative liability upon exercise of warrants
               (1,427
    
 
 
    
 
 
 
Balance, end of period
   $ 428      $ 7,223  
    
 
 
    
 
 
 
There were no transfers between fair value levels for the six months ended June 30, 2022 and the year ending December 31, 2021.
 
25

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
(a) Financial Risk Management
The Company is exposed in varying degrees to a variety of financial instruments related risks. The Board mitigates these risks by assessing, monitoring and approving the Company’s risk management processes.
(b) Credit Risk
Credit risk is the risk of loss associated with a counterparty’s inability to fulfill its payment obligations. The Company’s credit risk is primarily attributable to cash, lease receivables, other receivables, and notes receivable. The Company’s maximum credit risk exposure is equivalent to the carrying value of these instruments.
The risk exposure is limited to the carrying amounts at the statement of financial position date. The risk to cash deposits is mitigated by holding these instruments with regulated financial institutions. Lease receivables, notes receivables and other receivables credit risk arises from the possibility that principal and interest due may become uncollectible. The Company mitigates this risk by managing and monitoring the underlying business relationships.
The Company maintains cash with federally insured financial institutions. As of December 31, 2021, the Company exceeded federally insured limits by approximately $10,866. The Company did not exceed any federally insured limits at any of its financial institutions for the six months ended June 30, 2022. The Company has historically not experienced any losses in such accounts. As of June 30, 2022, the Company held approximately $9 in cash in a Canadian account that is denominated in C$.
As of June 30, 2022 and December 31, 2021, the maximum credit exposure related to the carrying amounts of accounts receivable, other receivable, notes receivable and lease receivables was $15,823 and $12,722, respectively.
(c) Liquidity Risk
Liquidity risk is the risk that the Company will not be able to meet its financial obligations associated with financial liabilities. The Company manages liquidity risk through the management of its capital structure. The Company’s approach to managing liquidity is to raise sufficient capital to settle obligations and liabilities when due.
The Company has the following obligations as of June 30, 2022, which are expected to be payable in the following respective periods:
 
    
Less than
1 year
    
1 to 3 years
    
3 to 5 years
    
Greater
than 5
years
    
Total
 
Accounts payable and accrued liabilities
   $ 19,422      $ 1,200      $ —        $ —        $ 20,622  
Convertible notes, notes payable and accrued interest
     8,235        74,699        —          —          82,934  
Contingent consideration payable
     —                    —          —              
Construction finance liability
               16,000        —          —          16,000  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 27,657      $ 91,899      $ —        $ —        $ 119,556  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
(d) Interest Rate Risk
Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates.
(e) Foreign Exchange Risk
The Company is exposed to exchange rate fluctuations between United States and Canadian dollars. The Company’s share price is denominated in Canadian dollars. If the Canadian dollar declines against the United States dollar, the United States dollar amounts available to fund the Company through the exercise of stock options or warrants will be less. The Company also has bank accounts with balances of $9 in Canadian dollars. The value of these bank balances if converted to U.S. dollars will fluctuate. While the Company maintains a head office in Canada where it incurs expenses primarily denominated in Canadian dollars, such expenses are a small portion of overall expenses incurred by the Company. The Company does not have a practice of trading derivatives and does not engage in “natural hedging” for funds held in Canada.
 
26

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
(f) Other Price Risk
Price risk is the risk of variability in fair value due to movements in equity or market prices. The Company is subject to risk of prices to its products due to competitive or regulatory pressures.
Note 16: SEGMENT INFORMATION
Reportable Segments
Operating segments are components of the Company that combine similar business activities, with activities grouped to facilitate the evaluation of business units and allocation of resources by the Company’s board of directors and management. As of June 30, 2022, the Company had two reportable segments:
 
   
THC Cannabis – Production and cultivation of THC cannabis, manufacturing and distribution of cannabis products to own dispensaries and third-party retail customers, ancillary services supporting wholesale operations, and retail sales direct to end consumers
; and 
 
   
CBD Wellness – Pure Ratios which encompasses the production and sale of CBD products to third-party customers
.
The results of each segment are regularly reviewed by the Company’s Chief Executive Officer, who is the Company’s chief operating decision maker, to assess the performance of the segment and make decisions regarding the allocation of resources. The Company’s chief operating decision maker uses revenue and net loss as measure of segment performance. There are no intersegment sales or transfers. All revenues are derived from customers domiciled in the United States and all assets are located in the United States.
The below table presents revenues, depreciation and amortization, and net (income) loss by type for the three and six months ended June 30, 2022 and 2021, as well as assets by type as of June 30, 2022 and December 31, 2021:
 
    
Three Months Ended June 30,
    
Six Months Ended June 30,
 
    
2022
    
2021
    
2022
    
2021
 
Net Revenues
                                   
THC Cannabis
   $ 28,195      $ 26,396      $ 53,978      $ 48,544  
CBD Wellness
     244        725        509        1,547  
Corporate
     —          —                        
    
 
 
    
 
 
    
 
 
    
 
 
 
Total Net Revenues
     28,439        27,121        54,487        50,091  
Depreciation and Amortization
                                   
THC Cannabis
     1,123        833        1,970        1,589  
CBD Wellness
                                   16  
Corporate
     —          28                  30  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total Depreciation and Amortization
     1,123        861        1,970        1,635  
Net (Income) Loss
                                   
THC Cannabis
     3,846        1,003        4,102        3,841  
CBD Wellness
     (104      817        (119      820  
Corporate
     2,809        4,403        8,467        12,651  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total Net Loss
   $ 6,551      $ 6,223      $ 12,450      $ 17,312  
 
Assets
  
June 30, 2022
    
December 31, 2021
 
THC Cannabis
   $ 318,795      $ 238,933  
CBD Wellness
     781        805  
Corporate
     881        15,801  
    
 
 
    
 
 
 
Total Assets
  
$
320,457
 
  
$
255,539
 
Goodwill assigned to the THC Cannabis segment as of June 30, 2022 and December 31, 2021 was $42,037 and $23,155, respectively. Intangible assets, net assigned to the THC Cannabis segment as of June 30, 2022 and December 31, 2021 were $54,239 and $26,246, respectively.
The Company did not have any Goodwill or intangible assets assigned to the CBD Wellness segment as of June 30, 2022 and December 31, 2021.
 
27

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
 
Note 17: SUPPLEMENTARY CASH FLOW INFORMATION
Changes in
non-cash
working capital:
 
    
June 30, 2022
    
June 30, 2021
 
Changes in operating assets and liabilities
                 
Accounts receivable and other receivables
   $ (2,766    $ (815
Inventory
     (5,302      (4,563
Prepaid expenses
     (318      50  
Deposits
     222        (70
Accounts payable and accrued liabilities
     4,939        65  
Taxes payable
     5,683        5,163  
    
 
 
    
 
 
 
     $ 2,458      $ (170
    
 
 
    
 
 
 
Supplemental disclosure of
non-cash
investing and financing activities:
 
 
  
June 30, 2022
 
  
June 30, 2021
 
Exchange of convertible debt to equity
   $ 3,122      $ 17,719  
    
 
 
    
 
 
 
Change in
right-of-use
assets and lease liabilities
   $ 8      $ 153    
    
 
 
    
 
 
 
Issuance of equity to pay contingent consideration
 
$
 
 
$
883
 
 
 
 
 
 
 
 
 
 
Issuance of debt to pay contingent consideration
 
$
 
 
$
485
 
 
 
 
 
 
 
 
 
 
Equity portion of warrants recorded through derivative liability
 
$
 
 
$
1,427
 
 
 
 
 
 
 
 
 
 
Issuance of equity for NECC pursuant to acquisition
   $ 18,200      $     
    
 
 
    
 
 
 
Property, plant, and equipment acquired through NECC acquisition
   $ 15,238      $     
    
 
 
    
 
 
 
Issuance of notes payable through NECC acquisition
   $ 2,000      $     
    
 
 
    
 
 
 
Inventory acquired through NECC acquisition
   $ 213      $     
    
 
 
    
 
 
 
Issuance of equity for Island pursuant to acquisition
   $ 6,245      $     
    
 
 
    
 
 
 
Issuance of warrants for Island pursuant to acquisition
   $ 732      $     
    
 
 
    
 
 
 
Property and equipment acquired through Island acquisition
   $ 2,214      $     
    
 
 
    
 
 
 
ROU asset and lease liability acquired through Island acquisition
 
$
10,227
 
 
$
 
 
 
 
 
 
 
 
 
 
Note payable acquired through Island acquisition
 
$
245
 
 
$
 
 
 
 
 
 
 
 
 
 
Issuance of notes payable through Island acquisition

   $ 10,000      $     
    
 
 
    
 
 
 
Inventory acquired through Island acquisition
   $ 3,072      $     
    
 
 
    
 
 
 
Issuance of debt to acquire property and equipment
   $ 14      $ 445  
    
 
 
    
 
 
 
Inventory acquired through issuance of note payable
   $ 163      $     
    
 
 
    
 
 
 
Cancellation of ROU asset and lease liability
  
$
2,020
 
  
$
  
 
 
  
 
 
 
  
 
 
 
Note payable issued to satisfy accrued expenses
  
$
961
 
  
$
  
 
 
  
 
 
 
  
 
 
 
 
   
Cash paid for interest for the six months ended June 30, 2022 and 2021 was $3,174 and $1,662, respectively.
 
   
Cash paid for income taxes for the six months ended June 30, 2022 and 2021 was $2,100 and $224, respectively.
Note 18: INCOME TAXES
The following table summarizes the Company’s income tax expense:
 
    
For the Three Months Ended June
    
For the Six Months Ended June 30,
 
    
2022
    
2021
    
2022
    
2021
 
Net loss before income taxes
   $ (3,504    $ (2,867    $ (5,960    $ (11,298
Income tax expense
     (3,042      (3,351      (6,480      (6,004
The Company has computed its provision for income taxes under the discrete method which treats the
year-to-date
period as if it were the annual period and determines the income tax expense or benefit on that basis. The discrete method is applied when application of the estimated annual effective tax rate is impractical because it is not possible to reliably estimate the annual effective tax rate. The Company believes the use of this discrete method is more appropriate than the annual effective tax rate method due to the early growth stage of the business. At this time, there is a high degree of uncertainty in estimating the Company’s annual
pre-tax
income and significant
non-deductible
expenses so the Company cannot reliably estimate the annual effective tax rate.
Internal Revenue Code (“IRC”) Section 280E denies, at the U.S. federal level, deductions, and credits attributable to a trade or business trafficking in controlled substances. Because the Company is subject to IRC Section 280E, the Company has computed its U.S. tax based on gross receipts less cost of goods sold. The tax provisions for the six months ended June 30, 2022 and 2021, have been prepared based on the assumption that cost of goods sold is a valid expense for income tax purposes.
The federal statute of limitation remains open for the 2018 tax year to the present. The state income tax returns generally remain open for the 2017 tax year through the present. Net operating losses arising prior to these years are also open to examination if and when utilized.
 
28

Note 19: SUBSEQUENT EVENTS
On July 13, 2022, Kathi Lentzsch resigned from her role as Chair of the Board, while remaining a Director and Chair of the Compensation Committee, and Mr. Robert Hunt was appointed Chair of the Board.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
This Quarterly Report on Form
10-Q
contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and may include statements concerning, among other things, our business strategy (including anticipated trends and developments in, and management plans for, our business and the markets in which we operate), financial results, the impact of
COVID-19
on our business, operations, and the markets and communities in which we, our clients, and partners operate, results of operations, revenues, operating expenses, and capital expenditures, sales and marketing initiatives and competition. In some cases, you can identify forward-looking statements because they contain words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “suggests,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These statements are not guarantees of future performance; they reflect our current views with respect to future events and are based on assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from expectations or results projected or implied by forward-looking statements.
We discuss many of these risks in other filings we make from time to time with the Securities and Exchange Commission (the “SEC”). Also, these forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report on Form
10-Q,
which are inherently subject to change and involve risks and uncertainties. Unless required by federal securities laws, we assume no obligation to update any of these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated, to reflect circumstances or events that occur after the statements are made. Given these uncertainties, investors should not place undue reliance on these forward-looking statements.
Investors should read this Quarterly Report on Form
10-Q
and the documents that we reference in this report and have filed with the SEC and on SEDAR, including Annual Report on Form
10-K,
filed with the SEC on April 18, 2022, with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements for the for the six months ended June 30, 2022 and 2021.
Unless the context otherwise indicates, when used in this Quarterly Report on Form
10-Q,
“4Front,” “the Company,” “we,” “us” and “our” refer to 4Front Ventures Corp., a British Columbia corporation, and its wholly owned subsidiaries on a consolidated basis.
Overview
4Front Ventures Corp. (“4Front” or the “Company”) exists pursuant to the provisions of the British Columbia Corporations Act. On July 31, 2019, 4Front Holdings LLC (“Holdings”) completed a Reverse Takeover Transaction (“RTO”) with Cannex Capital Holdings Inc. (“Cannex”) whereby Holdings acquired Cannex and the shareholders of Holdings became the controlling shareholders of the Company. Following the RTO, the Company’s SVS are listed on the Canadian Securities Exchange (“CSE”) under the ticker “FFNT” and are quoted on the OTC (OTCQX: FFNTF).
The Company has two primary operating segments: THC Cannabis and CBD Wellness. With regard to its THC Cannabis segment, as of June 30, 2022, the Company operates six dispensaries in Massachusetts, Illinois, and Michigan, primarily under the “MISSION” brand name. As of June 30, 2022, the Company operates three production facilities in Massachusetts, Illinois and California and produces the majority of products that are sold at its own Massachusetts and Illinois dispensaries. Also, as part of its THC Cannabis segment, the Company leases real estate and sells equipment, supplies and intellectual property to cannabis producers in the state of Washington.
 
29

While marijuana is legal under the laws of several U.S. states (with varying restrictions), the United States Federal Controlled Substances Act classifies all “marijuana” as a Schedule I drug, whether for medical or recreational use. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision.
The Company’s CBD Wellness segment is focused upon its ownership and operation of its wholly owned subsidiary, Pure Ratios Holdings, Inc. (“Pure Ratios”), a
CBD-focused
wellness company in California, that sells
non-THC
products throughout the United States.
Recent Developments
Merger with Island Global Holdings, Inc.
Please see Note 7 of the financial statements for a full description of the Company’s entrance into the Island Merger Agreement on March 30, 2022, and related transactions.
Changes to Composition of Board of Directors
On July 13, 2022, Kathi Lentzch resigned from her role as Chair of the Board, while remaining a Director and Chair of the Compensation Committee, and Mr. Robert Hunt was appointed Chair of the Board
Thut Resignation as Interim Chief Financial Officer
On June 9, 2022, Andrew Thut resigned his position as Interim Chief Financial Officer of the Company. Mr. Thut joined the Company in October 2014 as its Chief Investment Officer and was appointed to the position Interim Chief Financial Officer (in addition to his position as Chief Investment Officer) effective July 1, 2021. Mr. Thut will continue to serve as the Company’s Chief Investment Officer. Mr. Thut’s resignation from this position was not in connection with any known disagreement with the Company on any matter relating to the Company’s operations, policies, or practices, including accounting principles and practices.
Adams Appointment As Chief Financial Officer
Effective June 9, 2022, the Company’s board of directors appointed Keith Adams as the Company’s Chief Financial Officer. From November 2019 to present, Mr. Adams served as the Chief Financial Officer of LPF JV, LLC a privately-held California vertically integrated cannabis company that was recently acquired by StateHouse Holdings, Inc., formerly known as Harborside Inc. From July 2018 to November 2019, Mr. Adams worked as the Chief Accounting Officer of DionyMed Brands, Inc. (OTCMKTS: DYMEF), a multi-state cannabis brand, distribution and delivery platform supporting cultivators, manufacturers and brands in both medical and adult-use markets. From May 2016 to June 2018, Mr. Adams was the Chief Financial Officer at Efficient Power Conversion, a provider of gallium nitride (GaN)-based power management technology. Prior to this time, Mr Adams held various senior level finance jobs including CFO, CAO and others, mainly in the technology industry over the course of 25 years. Mr. Adams is licensed as a Certified Public Accountant and Certified Management Accountant. He also holds a Bachelor of Business Administration in Accounting from University of Wisconsin-Oshkosh.
There are no arrangements or understandings between Mr. Adams and any other persons pursuant to which he was appointed as an officer of the Company. Mr. Adams has no family relationships with any of the Company’s directors or executive officers, and, other than as described above, Mr. Adams does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation
S-K.
In connection with his appointment as Chief Financial Officer, Mr. Adams executed an offer letter pursuant to which the Company and Mr. Adams will enter into an employment agreement at a later date, with proposed terms that Mr. Adams would be entitled to an annual base salary of $275,000, eligible to earn
year-end
performance bonuses with a target bonus opportunity of 50% of his base salary, and an initial equity grant of 1,250,000 shares of the Company’s Subordinated Voting Shares, no par value per share, which would begin vesting in
one-third
increments beginning on the first anniversary of Mr. Adam’s first year of employment with the Company.
 
30

Feltham Termination
Effective June 14, 2022, the Company determined that the position of Chief Operating Officer was not needed at the present time, in order to further streamline the Company’s internal reporting structure. As such, Joseph Feltham was relieved of his duties as Chief Operating Officer of the Company, and a replacement for his position is not currently being pursued. The removal from employment of Mr. Feltham was not in connection with any known disagreement with the Company on any matter relating to the Company’s operations, policies or practices, including accounting principles and practices.
In connection with his removal from the Company, effective June 14, 2022 Mr. Feltham and the Company entered into a Separation, Transition, and Release of Claims Agreement (the “Feltham Separation Agreement”). The Feltham Separation Agreement was signed by all parties on July 14, 2022. Pursuant to the terms proposed by the Company for the Feltham Separation Agreement, Mr. Feltham will continue to receive a base salary of $11,538.46 bimonthly through December 31, 2022, and will retain the right to exercise previously vested options held by Mr. Feltham within 90 days of his termination date. Mr. Feltham is also eligible for a 2021 bonus payment
COVID-19
Pandemic
In March 2020, the World Health Organization (“WHO”) declared
COVID-19
a global pandemic, and the United States declared a national emergency with respect to
COVID-19.
The emergence of
COVID-19,
an extremely infectious airborne respiratory virus, caused a significant response on the part of many governments to contain it.
The full extent of the
COVID-19
pandemic impact continues to depend on future developments that remain highly uncertain and cannot be accurately predicted, including new information that may emerge concerning
COVID-19,
the actions taken to contain it or treat its impact, the identification and spread of
COVID-19
variants such as the Delta and the Omicron variants, the distribution of vaccines, the acceptance of vaccines and the implementation of vaccine mandates, and the economic impact on local, regional, national and international markets. Management continues to actively monitor the developments regarding the pandemic and the impact that the pandemic could have on our business, results of operations, financial condition, and most importantly the health and safety of our workforce. Given the continued volatility of the
COVID-19
pandemic and the global responses to curb its spread, we are not able to estimate the effects of the
COVID-19
pandemic on our results of operations, financial condition, or liquidity for 2022. Any recovery from negative impacts to our business and related economic impact due to the
COVID-19
pandemic may also be slowed or reversed by a number of factors, including the current widespread resurgence in
COVID-19
infections attributable to the Omicron variant, combined with the seasonal flu. As such, we are unable to reasonably estimate the duration of the pandemic or fully ascertain its long-term impact to our business.
War in Ukraine
In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements. The specific impact on our financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements.
Critical Accounting Policies and use of Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). We believe that several accounting policies are important to understanding our historical and future performance. We refer to these policies as critical because these specific areas generally require us to make judgments and estimates about matters that are uncertain at the time we make the estimate, and different estimates – which also would have been reasonable – could have been used. On an ongoing basis, we evaluate our estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Critical accounting policies and estimates are further discussed in our Annual Report on Form
10-K
for the year ended December 31, 2021, as filed with the SEC on April 18, 2022.
 
31

Results of Operations
Three Months Ended June 30, 2022 Compared With Three Months Ended June 30, 2021
The following table sets forth our consolidated statement of operations for the three months ended June 30, 2022 and 2021, and the change between the two years ($ in thousands):
 
    
For the Three Months Ended
June 30,
    
Change
 
    
2022
    
2021
    
$
    
%
 
Revenue from Sale of Goods
   $ 25,488      $ 24,452      $ 1,036        4
Real Estate Income
     2,951        2,669        282        11
  
 
 
    
 
 
    
 
 
    
 
 
 
Total Revenues
     28,439        27,121        1,318        5
Cost of Goods Sold
     (16,123      (10,816      (5,307      49
  
 
 
    
 
 
    
 
 
    
 
 
 
Gross profit
     12,316        16,305        (3,989      24
Total Operating Expense
     16,415        15,637        778        5
  
 
 
    
 
 
    
 
 
    
 
 
 
Income (Loss) from Operations
     (4,099      668        (4,767      714
Total Other income (expense), net
     595        (3,535      4,130        117
  
 
 
    
 
 
    
 
 
    
 
 
 
Net Loss Before Income Taxes
     (3,504      (2,867      (637      22
Income Tax Expense
     (3,042      (3,351      309        9
  
 
 
    
 
 
    
 
 
    
 
 
 
Net Loss from Continuing Operations
     (6,546      (6,218      (328      5
  
 
 
    
 
 
    
 
 
    
 
 
 
Net Loss
   $ (6,546    $ (6,218    $ (328      5
  
 
 
    
 
 
    
 
 
    
 
 
 
Revenue from Sale of Goods
Revenue from sale of goods for the three months ended June 30, 2022 was $25,488, an increase of $1,036 or 4% compared to the three months ended June 30, 2021. This increase is primarily due to increased revenue from the Company’s Brookline, MA and Calumet City, IL dispensaries as well as an increase in the Company’s wholesale revenue as it ramps those portions of its business in California, Illinois, and Massachusetts.
Real Estate Income
Real Estate Income from leasing cannabis production facilities for the three months ended June 30, 2022 was $2,951, an increase of $282 or 11% which is relatively flat compared to the $2,669 recognized for the three months ended June 30, 2021.
Cost of Goods Sold
Cost of goods sold (“COGS”) increase $5,307 for the three months ended June 30, 2022 from $10,816 to $16,123. COGS represent costs to cultivate and produce cannabis and CBD products that are produced in our owned facilities and are sold to third parties and through our owned dispensaries. For products that are purchased from third parties, COGS is the cost of inventory for sales to retail customers. This increase in COGS is largely attributed to increased third-party purchases to meet consumer demand at the Company’s retail locations, as well as the acquisition of Island and the continued integration of both Island and NECC.
 
32

Gross Profit
Gross profit for the for the three months ended June 30, 2022 was $12,316 or 43% of revenue compared to $16,305 or 60% of revenue for the three months ended June 30, 2021. The decrease in gross profit percentage of 17% is primarily due to a larger contribution of revenue from the Company’s wholesale business, increases in third-party inventory purchases, particularly to meet exceptional consumer demand in IL, and some anticipated pricing pressure in the Massachusetts market. To mitigate the pricing pressures in Massachusetts, the Company has improved vertical sell-through in its retail locations, a benefit of the high-quality flower and “fresh frozen” products added via the NECC acquisition.
Total Operating Expenses
Total operating expenses for the three months ended June 30, 2022 were $16,415, an increase of $778 or 5%, as compared to the three months ended June 30, 2021. This increase is primarily due to an increase in general and administrative expenses of $1,483, attributable to the addition of new operations in Brookline, MA, Holliston, MA and CA since the comparable period, offset by a decrease in equity based compensation of $3,947.
Total Other Income (Expense), net
Total Other Income (Expense) for the three months ended June 30, 2022 was $595, as compared to $(3,535) for the three months ended June 30, 2021. This is primarily driven by an increase in other income attributable to the write-off of a contingent liability consideration and a change in the fair value of derivative liability.
Six Months Ended June 30, 2022 Compared With Six Months Ended June 30, 2021
The following table sets forth our consolidated statement of operations for the six months ended June 30, 2022 and 2021, and the change between the two years ($ in thousands):
 
    
For the Six Months Ended
June 30,
    
Change
 
    
2022
    
2021
    
$
    
%
 
Revenue from Sale of Goods
   $ 48,571      $ 44,532      $ 4,039        9
Real Estate Income
     5,916        5,559        357        6
  
 
 
    
 
 
    
 
 
    
 
 
 
Total Revenues
     54,487        50,091        4,396        9
Cost of Goods Sold
     (28,717      (19,941      (8,776      44
  
 
 
    
 
 
    
 
 
    
 
 
 
Gross profit
     25,770        30,150        (4,380      15
Total Operating Expense
     31,110        29,129        1,981        7
  
 
 
    
 
 
    
 
 
    
 
 
 
Income (Loss) from Operations
     (5,340      1,021        (6,361      623
Total Other income (expense), net
     (620      (12,319      11,699        95
  
 
 
    
 
 
    
 
 
    
 
 
 
Net Loss Before Income Taxes
     (5,960      (11,298      5,338        47
Income Tax Expense
     (6,480      (6,004      (476      8
  
 
 
    
 
 
    
 
 
    
 
 
 
Net Loss from Continuing Operations
     (12,440      (17,302      4,862        28
  
 
 
    
 
 
    
 
 
    
 
 
 
Net Loss
   $ (12,440    $ (17,302    $ 4,862        28
  
 
 
    
 
 
    
 
 
    
 
 
 
Revenue from Sale of Goods
Revenue from sale of goods for the six months ended June 30, 2022 was $48,571, an increase of $4,039 or 9% compared to the six months ended June 30, 2021. This increase is primarily due to increased revenue from the Company’s Brookline, MA and Calumet City, IL dispensaries as well as an increase in the Company’s wholesale revenue as it ramps those portions of its business in California, Illinois, and Massachusetts.
 
33

Real Estate Income
Real Estate Income from leasing cannabis production facilities for the six months ended June 30, 2022 was $5,916, an increase of $357 or 6% which is relatively flat compared to the $5,559 recognized for the six months ended June 30, 2021.
Cost of Goods Sold
Cost of goods sold (“COGS”) increased $8,776 for the six months ended June 30, 2022 from $19,941 to $28,717. COGS represent costs to cultivate and produce cannabis and CBD products that are produced in our owned facilities and are sold to third parties and through our owned dispensaries. For products that are purchased from third parties, COGS is the cost of inventory for sales to retail customers. This increase in COGS is largely attributed to increased third-party purchases to meet consumer demand at the Company’s retail locations, as well as the acquisition of Island and the continued integration of both Island and NECC, is largely attributed to increased third-party purchases to meet consumer demand at the Company’s retail locations.
Gross Profit
Gross profit for the for the six months ended June 30, 2022 was $25,770 or 47% of revenue compared to $30,150 or 60% of revenue for the six months ended June 30, 2021. The decrease in gross profit percentage of 13% is primarily due to a larger contribution of revenue from the Company’s wholesale business, increases in third-party inventory purchases, particularly to meet exceptional consumer demand in IL, and some anticipated pricing pressure in the Massachusetts market. To mitigate the pricing pressures in Massachusetts, the Company has improved vertical sell-through in its retail locations, a benefit of the high-quality flower and “fresh frozen” products added via the NECC acquisition.
Total Operating Expenses
Total operating expenses for the six months ended June 30, 2022 were $31,110, an increase of $1,981 or 7%, as compared to the six months ended June 30, 2021. This increase is primarily due to an increase in general and administrative expenses of $3,962, attributable to the addition of new operations in Brookline, MA, Holliston, MA and CA since the comparable period offset by a decrease in equity based compensation of $3,947.
Total Other Income (Expense), net
Total Other Income (Expense) for the six months ended June 30, 2022 was $620, as compared to $12,319 for the six months ended June 30, 2021. This is primarily driven by a decrease in non-cash expenses including amortization of loan discount, change in fair value of derivative liability, and an increase in other income attributable to the write-off of a contingent liability consideration.
Non-GAAP
Financial and Performance Measures
In addition to providing financial measurements based on GAAP, we provide additional financial metrics that are not prepared in accordance with GAAP. Management uses
non-GAAP
financial measures, in addition to GAAP financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate the Company’s financial performance. Management uses the
non-GAAP
measurement of adjusted EBITDA, which we believe reflects our ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business, as it facilitates comparing financial results across accounting periods. We also believe that this
non-GAAP
financial measure enables investors to evaluate the Company’s operating results and future prospects in the same manner as management. This
non-GAAP
financial measures may also exclude expenses and gains that may be unusual in nature, infrequent or not reflective of the Company’s ongoing operating results. As there are no standardized methods of calculating
non-GAAP
measures, our methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similarly titled measures used by others. Accordingly,
non-GAAP
measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.
 
34

Adjusted EBITDA
Adjusted EBITDA is a financial measure that is not calculated in accordance with U.S. GAAP. Management believes that because adjusted EBITDA excludes (a) certain
non-cash
expenses (such as depreciation, amortization and stock-based compensation) and (b) expenses that are not reflective of the Company’s core operating results over time (such as restructuring costs, litigation or dispute settlement charges or gains, and transaction-related costs), this measure provides investors with additional useful information to measure the Company’s financial performance, particularly with respect to changes in performance from period to period. The Company’s management uses adjusted EBITDA (a) as a measure of operating performance, (b) for planning and forecasting in future periods, and (c) in communications with the Company’s board of directors concerning the Company’s financial performance. The Company’s presentation of adjusted EBITDA is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation and should not be used by investors as a substitute or alternative to net loss or any measure of financial performance calculated and presented in accordance with U.S. GAAP. Instead, management believes adjusted EBITDA should be used to supplement the Company’s financial measures derived in accordance with U.S. GAAP to provide a more complete understanding of the trends affecting the business.
Although adjusted EBITDA is frequently used by investors and securities analysts in their evaluations of companies, adjusted EBITDA has limitations as an analytical tool, and investors should not consider it in isolation or as a substitute for, or more meaningful than, amounts determined in accordance with U.S. GAAP. Some of the limitations to using
non-GAAP
measures as an analytical tool are (a) they do not reflect the Company’s interest income and expense, or the requirements necessary to service interest or principal payments on the Company’s debt, (b) they do not reflect future requirements for capital expenditures or contractual commitments, and (c) although depreciation and amortization charges are
non-cash
charges, the assets being depreciated and amortized will often have to be replaced in the future, and
non-GAAP
measures do not reflect any cash requirements for such replacements.
Adjusted EBITDA is defined by the Company as earnings before interest, taxes, depreciation and amortization, accretion, share-based compensation expense, legal settlement, change in value of derivative liability, foreign exchange gain (loss), loss on lease termination, other
non-cash
expenses, and
one-time
charges related to acquisition costs, financing-related costs, extraordinary
pre-opening
expenses and
non-recurring
expenses.
We consider these measures to be an important indicator of the financial strength and performance of our business. The following table reconciles adjusted EBITDA to its closest GAAP measure.
 
35

For the six months ended June 30, 2022 and 2021, adjusted EBITDA consisted of the following:
 
Six months ended June 30,
  
2022
    
2021
 
Net loss (GAAP)
   $ (12,440    $ (17,302
Interest income
     (2      (11
Interest expense
     9,274        5,362  
Amortization of loan discount upon conversion of debt to equity
     —          2,915  
Income tax expense
     6,480        6,004  
Depreciation and amortization
     4,689        2,166  
Accretion of liability expense
     7,400        —    
Equity based compensation
     1,428        5,375  
Change in contingent consideration payable
     (2,393      —    
Change in value of derivative liability
     (3,074      2,843  
Acquisition, transaction, and other
one-time
costs
     3,010        3,054  
Non-cash
inventory adjustment
     1,600        —    
Non-cash
lease expense
     2,213        1,765  
Loss on lease termination
     —          1,210  
  
 
 
    
 
 
 
Adjusted EBITDA
(Non-GAAP)
   $ 18,185      $ 13,381  
  
 
 
    
 
 
 
For the three months ended June 30, 2022 and 2021, adjusted EBITDA consisted of the following:
 
                           
Three months ended June 30,
  
2022
    
2021
 
Net loss (GAAP)
  
$
(6,546
  
$
(6,218
Interest income
  
 
—  
 
  
 
(8
Interest expense
  
 
5,047
 
  
 
2,901
 
Amortization of loan discount upon conversion of debt to equity
  
 
—  
 
  
 
—  
 
Income tax expense
  
 
3,042
 
  
 
3,351
 
Depreciation and amortization
  
 
2,894
 
  
 
1,120
 
Accretion of liability expense
  
 
3,694
 
  
 
—  
 
Equity based compensation
  
 
390
 
  
 
2,979
 
Change in contingent consideration payable
  
 
(2,393
  
 
—  
 
Change in value of derivative liability
  
 
(1,774
  
 
311
 
Acquisition, transaction, and other
one-time
costs
  
 
2,119
 
  
 
1,558
 
Non-cash
inventory adjustment
  
 
1,600
 
  
 
—  
 
Non-cash
lease expense
  
 
1,088
 
  
 
1,153
 
Loss on lease termination
  
 
—  
 
  
 
331
 
  
 
 
    
 
 
 
Adjusted EBITDA
(Non-GAAP)
  
$
9,161
 
  
$
7,478
 
  
 
 
    
 
 
 
Adjusted EBITDA should not be considered in isolation from, or as a substitute for, net loss. There are a number of limitations related to the use of adjusted EBITDA as compared to net loss, the closest comparable GAAP measure. Adjusted EBITDA excludes:
 
   
Interest income and expense
 
   
Current income tax expense
 
   
Non-cash
depreciation and amortization expense
 
   
Accretion expense related to a periodic update of the present value of a liability
 
   
Equity based compensation expense, which has been, and will continue to be for the foreseeable future, a significant recurring expense in our business and an important part of our compensation strategy
 
   
Legal settlements
 
   
Non-cash
change in fair value of derivative liability
 
   
Acquisition, transaction, and other expenses (income), which vary significantly by transaction and are excluded to evaluate ongoing operating results
 
36

Liquidity and Capital Resources
As of June 30, 2022 and December 31, 2021, we had total current liabilities of $63,392 and $48,838, respectively, and current assets of $47,125 and $50,874, respectively, to meet our current obligations. As of June 30, 2022, we had working deficit of $16,267, compared to working capital of $2,036, as of December 31, 2021. The decrease of $18,303 is driven primarily by a decrease in cash and increases in accounts payable and taxes payable, partially offset by increases in accounts receivable, other receivables, and inventory, and decreases in accrued expenses and other current liabilities, derivative liability, and current portion of convertible notes.
The Company is an early-stage growth company. It is generating cash from sales and is deploying its capital reserves to acquire and develop assets capable of producing additional revenues and earnings over both the immediate and near term. Capital reserves are being utilized for capital expenditures and improvements in existing facilities, product development and marketing, as well as customer, supplier and investor and industry relations.
Cash Flows
Net Cash (Used in) Provided by Operations
Net cash used in operating activities was $2,884 for the six months ended June 30, 2022, a decrease of $7,151 as compared to $4,267 of net cash provided by operating activities for the six months ended June 30, 2021. The decrease is due to a gain recognized on the fair valuation of the Company’s derivative liability compared to a loss in prior period and a prior period amortization of loan discount upon conversion of debt to equity, which was a one-time expense that was not incurred during the six months ended June 30, 2022. Additionally, the Company’s management of working capital resulted in a decrease in net working capital of $2,458.
Net Cash Used in Investing Activities
Net cash used in investing activities was $26,680 for the six months ended June 30, 2022, an increase of $15,944 as compared to $10,736 of cash used in investing activities for the six months ended June 30, 2021. The increase is primarily due to cash paid by the Company as part of the NECC acquisition for the six months ended June 30, 2022 as well as purchases of property, plant, and equipment of $2,249. The Company did not enter into an acquisition during the six months ended June 30, 2021. This increase is partially offset by more purchases of property and equipment by the Company during the six months ended June 30, 2021 than the six months ended June 30, 2022.
Net Cash Provided by Financing Activities
Net cash provided by financing activities was $13,015 for the six months ended June 30, 2022, an increase of $13,915 as compared to $900 of cash used in financing activities for the six months ended June 30, 2021. The increase is attributed to proceeds from the construction finance liability associated with the NECC acquisition during the six months ended June 30, 2022 of $16,000, partially offset by repayments of notes payable during the six months ended June 30, 2022 of $2,656.
 
37

Off-Balance
Sheet Arrangements
We do not have any
off-balance
sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
Critical Accounting Policies
We review new accounting standards as issued. Although some of these accounting standards issued or effective after the end of our previous fiscal year may be applicable to the Company, we have not identified any standards that we believe merit further discussion. We do not expect the adoption of any recently issued accounting pronouncements to have a significant impact on our financial position, results of operations, or cash flows.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
As a “smaller reporting company” as defined by Item 10 of Regulation
S-K,
the Company is not required to provide information required by this Item.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
As required by Rule
13a-15
under the Exchange Act, our management has carried out an evaluation, with the participation and under the supervision of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2022. Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating and implementing possible controls and procedures.
Material Weaknesses
A material weakness is a deficiency, or a combination of deficiencies, within the meaning of Public Company Accounting Oversight Board (“PCAOB”) Auditing Standard AS 2201, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.
Material Weaknesses in Internal Control
The Company did not fully design and implement effective control activities based on the criteria established in the COSO framework. The Company has identified deficiencies that constitute a material weakness, either individually or in the aggregate. This material weakness is attributable to the following factors:
 
   
We did not have sufficient accounting staff resources to timely perform closing and audit-related procedures.
 
   
We did not have effective controls over the review procedures for balance sheet account reconciliations and manual journal entries.
 
   
We did not have documented evidence of review procedures and did not have sufficient segregation of duties within our accounting function.
Due to the existence of the above material weakness, management, including the CEO and CFO, has concluded that our internal control over financial reporting was not effective as of June 30, 2022. This material weakness creates a reasonable possibility that a material misstatement to the consolidated financial statements will not be prevented or detected on a timely basis.
Management conducted its evaluation of disclosure controls and procedures under the supervision of our CEO and CFO. Based upon, and as of the date of, this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective as of June 30, 2022 due to the material weaknesses listed above.
 
38

Remediation of Material Weaknesses in Internal Control over Financial Reporting
The Company continues to strengthen our internal control over financial reporting and is committed to ensuring that such controls are designed and operating effectively. The Company is implementing process and control improvements to address the above material weakness as follows:
 
   
The Company will assess sufficient resources, both in accounting staff and related technology, needed to timely perform closing and audit-related procedures and align identified resources.
 
   
The Company will assess controls needed to effectively review procedures for balance sheet account reconciliations and manual journal entries and implement identified controls.
 
   
The Company will assess review procedures to have sufficient segregation of duties within our accounting function, then standardize and document such procedures for evidence of review.
The material weakness in the Company’s internal control over financial reporting will not be considered remediated until the remediated controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. The Company is working to have the material weaknesses remediated as soon as possible. However, there is no assurance that the remediation will be fully effective. As described above, the material weakness has not been remediated as of the filing date of this Form
10-Q.
If these remediation efforts do not prove effective and control deficiencies and material weaknesses persist or occur in the future, the accuracy and timing of the Company’s financial reporting may be materially and adversely affected.
Inherent Limitations on Effectiveness of Controls
Management recognizes that a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
Changes in Internal Control over Financial Reporting
The Company has begun implementing changes to strengthen the Company’s internal controls, including the hiring of a permanent CFO and Director of External Reporting, evaluating systems that could aid in improving controls, and implementing month end close procedures that include monthly flux analysis, Gross Margin analysis and performing balance sheet reconciliations. Other than those described above, there have been no changes in the Company’s internal control over financial reporting during the three months ended June 30, 2022 that have materially affected, or that are reasonably likely to materially affect, the Company’s internal control over financial reporting.
 
39

PART II—OTHER INFORMATION
Item 1. Legal Proceedings
On May 15, 2017, the Company’s wholly-owned subsidiary, 4Front Advisors, LLC, entered into an Application, Training, and Consulting Agreement with 5Seat Investment, LLC and Kanna. A dispute arose about amounts owed to the subsidiary under the agreement, and on May 17, 2022, the parties agreed to settle the matter for payment of $600 to the Company’s subsidiary.
On January 26, 2022, Savills, Inc. sued the Company in the U.S. District Court for the Southern District of New York. That lawsuit alleged that the Company had breached an alleged agreement with Savills under which the Company was allegedly required to pay Savills a percentage of savings realized under certain incentive programs offered in some jurisdictions, which Savills would assist the Company in obtaining. Savills claimed damages of approximately $19,000 in connection with its claim that it obtained benefits for the Company allegedly valued at over $129,000. The Company denied these allegations, denied the Company had obtained such benefits, disputed Savills’ characterization of the facts, and denied liability. The Company filed a counterclaim against Savills alleging breach of contract by Savills. On August 3, 2022, the parties reached a confidential settlement in principle and agreed to dismissal of all claims. In accordance with the order of dismissal, if no application to restore the litigation is submitted by September 6, 2022, the case will be dismissed without prejudice.
Apart from the foregoing and ongoing legal proceedings, from time to time, we may be subject to various other legal proceedings and claims that are routine and incidental to our business. Although some of the legal proceedings set forth herein may result in adverse decisions or settlements, management believes that the final disposition of such matters will not have a material adverse effect on our business, financial position, results of operations or cash flows.
Item 1A. Risk Factors
As a “smaller reporting company” as defined by Item 10 of Regulation
S-K,
we are not required to provide information required by this Item.
 
40

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On January 14, 2022, pursuant to a settlement agreement to settle an unsecured promissory note with an outstanding balance of $3,213 at December 31, 2021, the Company issued 6,235,512 SVS to LJM Investment Group.
On January 28, 2022, pursuant to an agreement and plan of merger whereby New England Cannabis Corporation, Inc., a Massachusetts corporation (“NECC”) became a wholly owned subsidiary of the Company, the Company issued 28,571,428 SVS, with a deemed value of $1.05 per share, or a total estimated valuation of $30,000,000 to Mr. Kenneth V. Stevens, the sole owner of all of the issued and outstanding capital stock of NECC.
On April 25, 2022, pursuant to an agreement and plan of merger whereby Island Global Holdings, Inc., a California corporation (“Island”) became a wholly owned subsidiary of the Company, the Company issued an aggregate of 8,783,716 SVS and warrants to purchase 2,999,975 SVS at a price of $1.00 per SVS to certain shareholders and debtholders of Island.
The foregoing transactions did not involve any underwriters, any underwriting discounts or commissions, or any public offering. We believe the offers, sales, and issuances of the above securities were exempt from registration under the Exchange Act (including Regulation D promulgated thereunder) by virtue of Section 4(a)(2) of the Securities Act, because the issuance of securities to the recipients did not involve a public offering. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions. All recipients had adequate access, through their relationships with us or otherwise, to information about us. The issuances of these securities were made without any general solicitation or advertising.
The Company did not repurchase any shares during the reporting period.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not Applicable.
Item 5. Other Information
The Company advanced its annual shareholder meeting from December to June, and held its annual shareholder meeting on June 22,
2022.
 
41

Item 6. Exhibits
 
Exhibit
Number
  
Exhibit Description
  
Form
  
Filing Date
  
Exhibit
Number
  
Filed
Herewith
  31.1    Certification of the Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act             x
  31.2    Certification of the Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act             x
  32.1    Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Rule 13a-14(b) Under the Securities Exchange Act of 1934 and Section 1350 of Chapter 60 of Title 18 of the United States Code *             x
101.INS    Inline XBRL Instance Document            
101.SCH    Inline XBRL Taxonomy Extension Schema Document            
101.CAL    Inline XBRL Taxonomy Extension Calculation Linkbase Document            
101.DEF    Inline XBRL Taxonomy Extension Definition Linkbase Document            
101.LAB    Inline XBRL Taxonomy Extension Label Linkbase Document            
101.PRE    Inline XBRL Taxonomy Extension Presentation Linkbase Document            
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)            
 
+
Indicates management contract or compensatory plan.
*
This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and it is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
 
42

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
   
4FRONT VENTURES CORP.
Date: August 15, 2022
   
By:
 
/s/ Leo Gontmakher
     
Leo Gontmakher
     
Chief Executive Officer and Director
     
(Principal Executive Officer)
Date: August 15, 2022
   
By:
 
/s/ Keith Adams
     
Keith Adams
     
Chief Financial Officer
     
(Principal Financial Officer)
 
43

Exhibit 31.1

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Leonid Gontmakher, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of 4Front Ventures Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 15, 2022    

/s/ Leonid Gontmakher

    Leonid Gontmakher, Chief Executive Officer
    (principal executive officer)

Exhibit 31.2

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Keith Adams, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of 4Front Ventures Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 15, 2022    

/s/ Keith Adams

    Keith Adams, Chief Financial Officer
    (principal financial and accounting officer)

Exhibit 32.1

Certifications of Chief Executive Officer and Interim Chief Financial Officer

pursuant to

18 U.S.C. Section 1350,

as adopted pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Leonid Gontmakher, Chief Executive Officer (principal executive officer) of 4Front Ventures Corp. (the “Company”), and Peter Rennard, Interim Chief Financial Officer (principal financial and accounting officer) of the Company, each hereby certifies that, to the best of his knowledge:

 

  1)

The Company’s Quarterly Report on Form 10-Q for three months ended March 31, 2022, to which this certification is attached as Exhibit 32.1 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 15, 2022

 

/s/ Leonid Gontmakher

Leonid Gontmakher

Chief Executive Officer

(principal executive officer)

 

/s/ Keith Adams

Keith Adams

Chief Financial Officer

(principal financial and accounting officer)

The foregoing certifications are being furnished pursuant to 18 U.S.C. Section 1350. They are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the Company, regardless of any general incorporation language in such filing.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings